Autologous Bone Marrow Mononuclear Cell Transplantation and Coronary Bypass Surgery for Treatment of Ischemic Heart Failure by Lehtinen, Miia
Department of Cardiac Surgery 
Heart and Lung Center 
Helsinki University Central Hospital 
 
 
 
 
 
AUTOLOGOUS BONE MARROW MONONUCLEAR CELL 
TRANSPLANTATION AND CORONARY BYPASS SURGERY FOR 
TREATMENT OF ISCHEMIC HEART FAILURE 
 
 
 
 
 
 
Miia Lehtinen 
 
 
 
ACADEMIC DISSERTATION 
To be publicly discussed, with the permission of the Faculty of Medicine,  
University of Helsinki, in the Lecture Hall 4 of Meilahti Tower Hospital, Haartmaninkatu 4, on Friday 
May 8th, 2015, at noon 
  
	   2	  
Supervisors:  
Docent Antti Vento  
Department of Cardiac Surgery 
Heart and Lung Center 
Helsinki University Central Hospital 
Helsinki, Finland 
 
Tommi Pätilä, MD, PhD 
Department of Cardiothoracic Surgery 
Hospital for Children and Adolescents  
Helsinki University Central Hospital  
Helsinki, Finland  
 
Professor Ari Harjula 
Department of Cardiac Surgery 
Heart and Lung Center 
Helsinki University Central Hospital 
Helsinki, Finland  
 
Reviewers:  
Professor Petri Lehenkari 
Department of Anatomy and Cell Biology 
University of Oulu 
Oulu, Finland  
  
Docent Ari Mennander 
Heart Center 
Tampere University Hospital 
Tampere, Finland  
 
Opponent:  
Professor Philippe Menasché 
Université Paris Descartes 
Department of Cardiac Surgery 
Hôpital Européen Georges Pompidou  
Paris, France 
 
 
ISBN 978-951-51-0988-0 (paperback) 
ISBN 978-951-51-0989-7 (PDF) 
 
Helsinki 2015, Unigrafia  
	   3	  
Table of Contents 
Abstract	  .............................................................................................................................	  5	  
List of original publications	  ...............................................................................................	  7	  
Abbreviations	  ....................................................................................................................	  8	  
1 Introduction	  ..................................................................................................................	  11	  
2 Review of the literature	  ................................................................................................	  12	  
2.1 Heart failure	  .......................................................................................................................	  12	  
2.1.1 Epidemiology and etiology	  ..................................................................................................	  12	  
2.1.2 Coronary artery disease	  ........................................................................................................	  12	  
2.1.3 Systolic and diastolic heart failure	  .......................................................................................	  13	  
2.1.4 Cardiac remodeling	  ..............................................................................................................	  14	  
2.1.5 Symptoms and clinical course of heart failure	  .....................................................................	  15	  
2.1.6 Medical treatment for ischemic heart failure	  .......................................................................	  16	  
2.1.7 Interventional treatment for ischemic heart failure	  ..............................................................	  17	  
2.1.8 Cardiac imaging of heart failure	  ..........................................................................................	  19	  
2.2 Heart regeneration	  .............................................................................................................	  23	  
2.3 Cell therapy for heart failure	  .............................................................................................	  24	  
2.3.1 Bone marrow cells	  ...............................................................................................................	  24	  
2.3.2 Timing	  .................................................................................................................................	  25	  
2.3.3 Cell delivery routes	  ..............................................................................................................	  25	  
2.3.4 Other cell types	  ....................................................................................................................	  26	  
3 Aims of the study	  ..........................................................................................................	  29	  
4 Methods	  ........................................................................................................................	  30	  
4.1 Agreements and notifications	  .............................................................................................	  30	  
4.2 Patient selection	  ..................................................................................................................	  30	  
4.3 Cell transplantation procedure	  ..........................................................................................	  30	  
4.3.1 BMMC harvesting	  ...............................................................................................................	  30	  
4.3.2 Randomization	  .....................................................................................................................	  31	  
4.3.3 Operation	  .............................................................................................................................	  31	  
4.3.3 Hemodynamic monitoring during surgery (Study II)	  ...........................................................	  32	  
4.4 Intensive-care unit stay (Study II)	  ......................................................................................	  32	  
4.5 Follow-up	  ............................................................................................................................	  32	  
4.6 Cardiac MRI (Studies I, III, IV)	  .........................................................................................	  33	  
4.7 Nuclear imaging with SPECT and PET (Studies I, III)	  .....................................................	  33	  
4.7.1 Evaluation of nuclear imaging data	  .....................................................................................	  34	  
4.8 Laboratory parameters, NYHA class, and health-related quality of life (Studies I, II, IV)	  35	  
4.9 Statistical analysis	  ..............................................................................................................	  35	  
5 Results	  ..........................................................................................................................	  36	  
5.1 Patient characteristics	  ........................................................................................................	  36	  
5.2 Perioperative safety of intramyocardial BMMC therapy (Study II)	  ..................................	  38	  
	   4	  
5.3 Predicting myocardial function recovery after revascularization with SPECT and PET 
(Study III)	  ................................................................................................................................	  38	  
5.4 Effects of intramyocardial BMMC therapy during 1-year follow-up (Study I)	  .................	  39	  
5.5 Effects of intramyocardial BMMC therapy during long-term follow-up (Study IV)	  .........	  42	  
6 Discussion	  .....................................................................................................................	  44	  
6.1 Selection of patients	  ............................................................................................................	  44	  
6.2 Safety	  ..................................................................................................................................	  44	  
6.3 Assessing myocardial function, morphology, and viability with imaging methods	  ............	  45	  
6.3.1 Predicting benefits from revascularization with SPECT and PET	  .......................................	  45	  
6.3.2 Evaluating effects of BMMC therapy with MRI	  .................................................................	  47	  
6.4 Effects of intramyocardial BMMC injections as an adjunct to CABG	  ..............................	  48	  
Summary and conclusions	  ...............................................................................................	  52	  
Acknowledgements	  ..........................................................................................................	  53	  
7 References	  .....................................................................................................................	  55	  
 
  
	   5	  
Abstract 
 
Background: Worldwide, the leading cause of morbidity and mortality is heart failure. It is 
most often caused by coronary artery disease (CAD) and myocardial infarction (MI), which 
causes death of myocardial tissue. Although coronary interventions such as coronary bypass 
graft surgery (CABG) can restore blood flow to ischemic areas, and established 
pharmacotherapy for heart failure exists, no treatment available in the clinics can regenerate 
the dead cardiomyocytes. For surgical treatment, patients with heart failure represent a 
challenge, as they are prone to surgical complications, and suitable preoperative imaging 
modalities to assess possible benefit from surgery are few.  
Aims: Cell therapies have recently emerged as a possible alternative for treating heart failure. 
We wanted to explore the capacity of autologous bone marrow mononuclear cells to 
regenerate myocardial tissue as an adjunct to CABG. The aim was to assess the therapy’s 
safety and detect the cells’ possible effects on cardiac function and viability. In addition, we 
investigated whether it would be possible to predict benefit from CABG in these heart-failure 
patients with 3-vessel CAD with the aid of combined nuclear imaging data. For this, we used 
18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to measure cardiac 
viability, and 99mtechnetium-tetrofosmin single-photon emission computed tomography 
(99mTc-SPECT) to measure cardiac perfusion.  
Methods: Between 2006 and 2010, we enrolled 104 patients scheduled for CABG who 
suffered from CAD and ischemic heart failure. Preoperatively, pharmacotherapy was 
optimized, after which 39 patients still had left ventricular ejection fraction (LVEF) ≤45%. 
These patients received injections of bone marrow mononuclear cells (BMMCs) (N=20) or 
vehicle (N=19) intraoperatively into the myocardial infarction border area in a randomized 
and double-blind manner. During surgery and at the intensive care unit (ICU), the patients’ 
hemodynamics, arterial blood gases, systemic venous oxygen level, blood glucose, acid-base 
balance, lactate, hemoglobin, body temperature, and diuresis as well as medications needed 
were monitored and recorded every four hours throughout the first postoperative 24 hours. 
BMMC effects on the heart were evaluated by use of pre- and 1-year postoperative cardiac 
magnetic resonance imaging (MRI), FDG-PET, and 99mTc-SPECT and by measuring pro-B-
type amino-terminal natriuretic peptide (proBNP) levels. As we later decided to extend the 
follow-up, these same variables, except for nuclear imaging data, as well as current quality of 
life were measured at a late follow-up visit in 2013. For this, we could contact 36 of the 39 
patients recruited for the original study, of which 30 participated in the extended follow-up.  
Preoperatively, we also analyzed FDG-PET and 99mTc-SPECT data by using three 
quantitative techniques with a software tool to measure defects with hypoperfused but viable 
and non-viable myocardium in 15 control patients. One method used solely PET, two others 
combined PET and SPECT at different thresholds. As a reference, we used change in LV 
function and volume by MRI.  
Results: During the first-year follow-up, improvement was similar in both groups in LVEF, 
the predefined primary end-point measure (P=0.59), and similar improvement also occurred 
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in local wall thickening (WT) (P=0.68) in the injected segments. Neither changes in viability 
by PET and SPECT and levels of proBNP differed between these groups. Myocardial scar 
size by MRI in injected segments rose by a median of 5.1% in the control group (interquartile 
range, IQR -3.3 to 10.8) but fell by 13.1% in the BMMC group (IQR -21.4 to -6.5) 
(P=0.0002). During surgery and ICU stay, hemodynamics, arterial blood gases, systemic 
venous oxygen level, blood glucose, acid-base balance, lactate, hemoglobin, body 
temperature, and diuresis and levels of medications administered were similar between the 
study groups. 
For the extended follow-up, the median period was 60.7 months (IQR 45.1 to 72.6). No 
statistically significant difference was observable in change in proBNP values or in quality of 
life between groups. LVEF in both groups remained similarly improved (P=0.65), as also did 
WT (P=0.43). For controls, scar size in injected segments increased with a median of 2% 
(IQR -7 to 19); for BMMC patients it remained reduced with a median change of -17% (IQR -
30 to -6) (P=0.01).  
When assessing the benefit-predictive capacity of the two techniques combining FDG-PET 
and 99mTc-SPECT with different thresholds and one technique using FDG-PET data only, no 
correlation appeared with preoperative PET- or PET-SPECT-derived viable or non-viable 
tissue, when compared with global functional outcome (change in LVEF) or local change in 
WT.  
Conclusions: In patients with 3-vessel disease and heart failure, the three techniques using 
SPECT perfusion and PET viability imaging data failed to predict the functional benefit 
received from CABG. Thus, these imaging modalities may provide no additional advantage to 
preoperative patient selection, which should be considered when planning treatment for this 
patient group in the clinics.  
In the treatment of chronic ischemic heart failure, during surgery and perioperatively in the 
ICU, both intramyocardial BMMC and placebo injections appear safe. Although failing to 
affect cardiac function, combining intramyocardial BMMC therapy with CABG can 
sustainably reduce scar size. 
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1 Introduction 
	  
Heart failure is notorious for putting a strain on millions of patients’ quality of life and a 
burden on national economies (Stewart et al. 2010; Teng et al. 2010). Approximately 15 
million people in Europe (McMurray et al.2012) suffer from this condition. 
The most common underlying pathology behind heart failure is coronary artery disease 
(CAD), a disease compromising blood flow in coronary arteries supplying the heart, thus 
causing ischemia. Diseased arteries present with narrowed lumens with atherosclerotic 
plaques. These plaques are susceptible to shear stress; they rupture easily, leading to 
myocardial infarction and tissue death. 
The disease causes restrictive symptoms such as chest pain and fatigue, severely impairing 
quality of life. The further the coronary artery disease develops towards ischemic heart 
failure, the scarcer and less efficient become treatment options. Today, applicable treatment 
options include pharmacotherapy, coronary artery bypass surgery (CABG), and, at the end-
stage of heart failure, heart transplantation. Despite these, prognosis remains sinister: mean 
survival time after first hospitalization for heart failure is approximately 2 years (Jhund et al. 
2009). 
A major problem is that patients with ischemic heart failure are often old and have many 
comorbidities (Ferguson et al. 2002; Braunwald 2013). Thus, patients possibly benefiting 
from revascularization surgery require proper selection. But although surgical treatment 
options could be beneficial (Passami et al. 1985; Velazquez et al. 2011), severely ill patients 
may not even survive surgery.  
Since 2001, the focus of attention has been on an interesting notion: bone marrow-derived 
cells could potentially regenerate dead myocardium and improve cardiac function (Orlic et al. 
2001). After promising results in animal studies, clinical trials have also been numerous 
(Donndorf et al. 2011; Delewi et al. 2012), by varying approaches: with intramyocardial or 
intracoronary injection, given shortly after myocardial infarction or in a chronic stage of 
CAD. After a decade of vigorous investigation, results, however, remain mixed. 
Trials have suffered from heterogeneity in study methods and quality (Francis et al. 2013; 
Leri et al. 2013), especially concerning intramyocardial cell therapy, which is often combined 
with CABG. We set up a prospective, controlled, double-blinded trial evaluating the safety 
and efficacy of bone-marrow cell injections as an adjunct to CABG in treatment of ischemic 
heart failure. We also investigated the predictive role of preoperative nuclear medicine 
imaging for outcome of revascularization in ischemic heart failure. 
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2 Review of the literature 
2.1 Heart failure 
2.1.1 Epidemiology and etiology 
Heart failure is one of the major causes for morbidity and mortality in the world. Its 
prevalence increases with age (Ho et al. 1993): it affects 1 to 2% of adults and even over 10% 
of people aged more than 70 years (Mosterd et al. 2007). 
Heart failure is a common condition resulting from various diseases, including hypertension, 
valvular diseases, hypertrophic cardiomyopathy, and congenital heart diseases, but the most 
common culprit is coronary artery disease (CAD).  
2.1.2 Coronary artery disease 
CAD causes lipid accumulation in the heart vessels, the coronary arteries. The part of the 
vessel most susceptible to this lipid accumulation is the layer right next to the arterial lumen, 
the intima. It loses its normal cellular structure and function and becomes vulnerable to the 
shear stress of blood flow. When the amount of intimal lipid further increases, an extracellular 
lipid pool develops, covered by a fibrous collagen-rich cap (Pasterkamp et al. 2000). This 
atherosclerotic plaque is unstable and may ultimately rupture from the vessel wall, causing 
local thrombosis and obstruction leading to ischemia and myocardial damage (Pasterkamp et 
al. 2000).  
When ischemia has struck the heart, damage to the myocardium remains reversible for less 
than 30 minutes; after that, damaged myocardium is progressively destroyed (Jennings et al. 
1960). Within 6 hours, programmed cell death, apoptosis, and necrosis of the insulted 
myocardial area is complete, extending from the subendocardium to the subepicardium 
(Reffelman et al. 2002; Reimer et al. 1977; Buja et al. 2005).  
The dead heart muscle tissue is then progressively replaced by a fibrotic scar (Frangoannis 
2006). First, within 24 hours, cardiomyocytes become swollen, release their intracellular 
proteins to the extracellular space, and become necrotic, after which, inflammatory response 
proceeds and polymorphic leukocytes infiltrate the infarction area. Within one week after 
infarction, in an attempt to repair the damaged tissue, lymphocytes and macrophages emerge, 
and phagocytosis of the dead cells begins, starting from the infarction periphery towards its 
center. These cells stimulate fibroblasts, which start their proliferation and collagen 
production. Extracellular matrix also transforms. First, a fibrin-based matrix forms, promoting 
cell proliferation and migration at the site of infarction. This preliminary matrix is then 
replaced by a more organized network of fibronectin and hyaluronan. To provide nutrients 
and oxygen to the site of healing with active metabolism, neovessels form. During the 
following month, as maturation of the myocardial scar proceeds, with increasing amounts of 
cross-linked collagen, the tensile strength of the scar is enhanced, but the elasticity of the 
heart is compromised, leading to tissue stiffness.  
However, ischemia’s effects are not restricted to the necrotic area killed by ischemia. During 
ischemia, a large area next to the dying myocardial tissue undergoes pathological changes due 
to oxygen shortage, but this area remains potentially viable even though it also often presents 
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with impaired contractile function. If reperfused, these viable cells may recover from the 
detrimental changes induced by ischemia and regain normal function, or progress to cell death 
(Lim et al.1999).  
In the area of viable but dysfunctional myocardium, some cells are stunned (Braunwald and 
Kloner 1982). Stunned myocardium usually recovers spontaneously after reperfusion, but 
myocardial dysfunction may be present for several days despite normalized coronary blood 
flow (Bolli et al.1988). The mechanism of stunning involves induction of oxygen radicals, 
modification of calcium homeostasis, and a contracted protein structure (Kloner 2001a and 
2001b).  
Myocardium may also go into hibernation if hypoperfusion persists chronically (Braunwald 
and Rutherford 1986). After revascularization, the hibernating myocardium is capable of 
regaining normal contractile function. The chronic ischemic burden of hibernating 
myocardium is reflected in microscopic changes: whereas stunned myocardium shows 
minimal microscopic change, hibernating myocardium has a shape indicative of degenerating 
cardiomyocytes, with large perinuclear glycogen and mitochondria pools and myofilaments 
restricted to the cell periphery (Kloner 2001a and 2001b). 
In the past, acute heart infarction was immediately lethal. Today, mortality has decreased 
thanks to established medical treatment. Even acutely administered treatment cannot, 
however, heal myocardium affected by infarction, leaving the heart permanently damaged. 
Gradually proceeding atherosclerotic arterial obstruction compromises cardiac blood flow and 
further impairs myocardial function. Thus, morbidity remains high (Chen et al. 2011), leading 
to a dramatic increase in number of patients suffering from heart failure. 
2.1.3 Systolic and diastolic heart failure 
Regardless of the underlying pathology, the failing heart activates specific pathological 
processes. In systolic type heart failure, deteriorating contractile capacity fails to pump 
enough blood into the circulation. This leads to a reduced ejection fraction (EF), the 
proportion of ventricular blood pumped to the aorta during a contraction. Today, the systolic 
type of heart failure is more often referred to as heart failure with reduced ejection (HFrEF). 
Its leading cause is CAD and myocardial infarction. The infarction leads to loss of the 
sufficient systolic function by causing cell death and loss of contractile activity in the affected 
zone (Dorn et al. 2009; Fraccarollo et al. 2012). With failing contractility, the hemodynamic 
burden increases and mechanical forces stretch the abnormally stressed tissue (Dorn et al. 
2009), contributing to systolic failure. 
In the diastolic type (heart failure with preserved ejection fraction, HFpEF), ventricular filling 
is impaired, but not contractility, as in HFrEF;this leads to a decreased amount of blood 
passing from the heart to the circulation, although the ejection fraction is not affected. This 
subtype of heart failure has long been poorly recognized, but now the estimate is perhaps even 
50% of heart failure patients have a preserved ejection fraction (Burchfield et al. 2013). 
Initially, HFpEF was considered to result from pathological characters of the left ventricle 
(LV), leading to diastolic stiffness, prolonged isovolumic LV relaxation, and slow LV filling 
(Soufer et al.1985). It now seems, however, that pathological LV is maybe not the actual 
culprit but is suffering from dysfunctional filling caused by volume overload, insufficiency of 
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perfusion, excessive volume resulting from extrinsic factors, or inadequate filling times 
(Burchfield et al. 2013). Patients with vascular stiffening and vascular dysfunction may also 
be more predisposed to HFpEF (Owan et al. 2006, Melenovsky et al. 2007). 
Often, heart failure is a combination of these two. To compensate for these changes, the 
sympathetic nervous system becomes activated. The heart rate rises, and with the increased 
workload, myocardial circulation suffers. The renin-angiotensin-aldosterone (RAA) system is 
also stimulated, which leads to vasoconstriction, reduced renal blood flow leading to fluid 
retention, and elevated blood pressure, all further burdening the heart. Angiotensin II affects 
the heart mainly through its receptor type 1, the activation of which causes vasoconstriction, 
and induces hypertrophy and fibrosis in cardiac muscle. It also causes an increase in secretion 
of aldosterone, further inducing cardiac fibrosis, to fight against the overwhelming workload 
of the failing heart (Fyhrquist and Saijonmaa 2008) 
As the increasing workload stretches the atria and ventricles, B-type natriuretic peptide (BNP) 
levels undergo stimulation to increase. It tries to cause vasodilatation, increased excretion of 
natrium and water, and reduced activity of both the RAA system and sympathetic nervous 
system. However, its efforts fail to counteract the accelerating deleterious processes leading to 
heart failure (Kupari and Lommi 2004). 
2.1.4 Cardiac remodeling 
Continuous ventricular wall stress and neurohumoral alterations induce morphological 
changes, a process called cardiac remodeling. Although first an adaptive process, it soon 
causes the heart to decompensate (Mann et al. 1999). Progressive remodeling is associated 
with a poor prognosis (Cohn et al. 2000). 
The remodeling process of ischemic heart failure has been under extensive study, as it 
represents a logical course of pathological molecular events leading to visible changes in 
heart morphology. In the ischemic heart, the magnitude of cardiac remodeling depends 
directly on the extent of myocardial damage, infarction-caused (Fraccorollo et al. 2012). In 
the healing process after myocardial infarction, as the inflammatory response subsides and 
cardiac fibroblasts proliferate, the resulting tight, fibrotic scar, with significant tensile 
strength, serves to prevent rupture. Even though this process is essential for the post-insult 
heart to continue functioning, the remodeling process continues progressively in response to 
increases in wall stress, causing compensatory molecular, histological and morphological 
heart changes (Gajarsa et al. 2011).  
As part of the remodeling process, intracellular adaption of the cardiomyocytes is evident. In 
addition to apoptotic and necrotic processes of the dying heart muscle, as a response to the 
stress, autophagy occurs, the role of which is debatable: it may be adaptive, serving to 
promote cell survival, or maladaptive, contributing to the process of cell death (Burchfield 
2013). Another warning of stress and pressure overload is cardiomyocyte hypertrophy. 
Similarly with physiological (exercise) hypertrophic growth, in this pathological growth, 
increased expression occurs of genes responsible for cardiomyocyte structure, ion transport, 
and proteolysis (Sheehy 2009). However, in the disease process, cardiomyocyte growth is so 
overwhelming that adaptive capillary growth fails to meet its oxygen demand, leading to 
further hypoxia (Shiojima et al. 2005).  
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The pathology of heart failure is also linked to changes in the immune system. The immune 
system plays a significant role in remodeling, activating many inflammatory pathways, 
including the complement system, T cells, and the formation of autoantibodies (Aukrust et al. 
2001; Diwan et al. 2003; Caforio et al. 2007). If activation persists, these inflammatory 
processes may cause long-term heart injury. 
 
Probably the most distinctive feature of ventricular remodeling is the accumulation in the 
heart of fibrosis. This excessive fibrotic extracellular matrix provokes contractile dysfunction 
and functions as an arrhytmogenic area (Spinale et al. 2007), leading to increased morbidity 
and mortality (Assomull et al. 2006; Yan et al. 2006). Induced by pathological stress, cardiac 
fibroblasts proliferate and differentiate into contracting myofibroblasts which secrete collagen 
I, collagen III, and fibronectin into the extracellular matrix (Spinale et al. 2007). In addition to 
fibrosis aggravating the risk for arrhythmias, rhythm disturbances can also derive from 
pathological electrophysiological changes in the heart, causing disordered electrical currents 
arising from prolongation of ventricular action potentials (Burchfield 2013). 
2.1.5 Symptoms and clinical course of heart failure 
The symptoms of heart failure are dyspnea, swelling, fatigue, and chest pain (angina pectoris). 
Dyspnea occurs when fluid accumulates in the lungs; fluid accumulation in the lower 
extremities, usually in the ankles, causes swelling. Breathing is difficult, especially when 
supine because of larger intrathoracic volume and pressure.  A deteriorated ability to 
withstand exercise causes weakness and fatigue. Increased cardiac stress demands more 
oxygen, leading to myocardial ischemia and chest pain. Symptom severity can be classified 
according to the New York Heart Association (NYHA) classes (Table 1).  Symptom severity 
often fails to correlate with ventricular function, however. Although symptom severity and 
survival are clearly related to each other, patients with mild symptoms may still have worse 
prognosis, with a relatively high risk of hospitalization and death (McMurray et al. 2012). 
Sudden worsening of symptoms may occur due, for example, to infections or nutritional 
changes, and cause hospitalization periods. Heart failure is one of the most common reasons 
for recurrent hospitalizations in those of older age (Jencks et al. 2009) and, in western 
countries, these hospitalizations are a major economic burden. 
 
 
 
 
 
Table 1. New York Heart Association classes. 
 
A key characteristic of heart failure is inevitable disease progression. Within five years after 
diagnosis, as many as half the patients die (Stewart et al. 2010; Chen et al. 2011).     
Class Description 
NYHA 1 no limitation of physical activity 
NYHA 2 slight limitation of physical activity 
NYHA 3 marked limitation of physical activity 
NYHA 4 unable to perform any physical activity without discomfort 
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2.1.6 Medical treatment for ischemic heart failure 
Since heart failure is a condition caused by multiple diseases, the main goal is to treat these 
diseases. In the case of CAD, a major focus is on reducing the levels of cholesterol, the lipid 
accumulating in arteries. An established group of medicines to counteract this process is the 
statins. They execute their effect by inhibiting the 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase. This enzyme is engaged in production of cholesterol in the liver.  In 
addition, CAD patients benefit from medicines improving blood circulation. These include 
acetosalisylic acid and clopidogrel; for CAD, statins and these two have proven important for 
improving these patients’ prognosis (Task Force Members 2013). 
Medication necessary for all heart-failure patients aims at 1) alleviating symptoms; 2) 
preventing worsening of heart failure; 3) improving prognosis. Because different drug groups 
often affect different combinations of these aims, multiple drugs must be given in 
combination to achieve the desired outcome. 
In easing fluid retention symptoms, dyspnea and swellings, an effective medication is the 
diuretics. They remove salt and water from the kidneys by preventing reabsorption of sodium 
chloride.  One of them, spironolactone, has even shown an effect on prognosis in HFrEF (Pitt 
et al. 1999). It is speculated (Kupari and Lommi 2004) that other diuretics might even cause 
activation of a vicious circle for heart failure, as they induce activation of the RAA system. 
Thus, a combination of drugs counteracting RAA system effects is recommended. 
Beta-blockers act through blocking adrenergic beta-receptors and thus reducing heart rate 
giving the heart time to relax and fill with blood more properly between contractions. They 
also deactivate the induced renin-angiotensin system and lower blood pressure. This can also 
be accomplished by drugs inhibiting an enzyme that converts angiotensin I to angiotensin II 
(angiotensin-converting enzyme inhibitors, ACE-I) or by blocking angiotensin-receptor type I 
(angiotensin-receptor blockers, ARB). All of these three groups of pharmaceuticals have 
improved systolic heart-failure patients’ prognosis (The SOLVD Investigators 1991; Pfeffer 
et al. 1992; Packer et al. 1996; CIBIS-II Investigators and Committees 1999; MERIT-HF 
Study group 1999; Cohn et al. 2001; Dargie et al. 2001; Packer et al. 2001; Granger et al. 
2003). 
Digoxin alleviates heart-failure symptoms and reduces hospitalizations when combined with 
ACE-I and diuretics (Digitalis Investigation Group 1997). It increases cardiac inotropy by 
blocking sodium pumps on cell membranes, reduces sodium re-uptake in kidneys, and 
dampens sympathetic activation. 
Calcium-channel blockers and nitrates can be useful, both of them causing vasodilation 
helping coronary blood flow and alleviating symptoms of chest pain and dyspnea. Despite 
their alleviating effects on symptoms, they have no effect on a heart-failure patient’s 
prognosis (Kupari and Lommi 2004). 
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2.1.7 Interventional treatment for ischemic heart failure 
Surgical techniques 
Since one of the major pathologies behind heart failure is CAD, CABG is a logical surgical 
treatment alternative. Its aim is to redirect blood back to the areas with obstructed arteries and 
thus, with impaired blood flow. In addition to non-viable necrotic tissue killed by ischemia, 
these areas contain heart muscle tissue that has reserved its viability and, after return of blood 
flow, can perform normal contractile myocyte function. As mentioned in section 2.1.2, these 
areas are called “stunned” if the ischemia time has been short and reversible, and 
“hibernating” if ischemic conditions have been evolving and continuing for a long time. 
These areas are an excellent target for revascularization procedures (Kloner et al. 2001b) 
CABG has established its position especially in treatment of patients with triple-vessel disease 
or stenosis of the left main coronary (Authors/Task Force Members 2012). In addition, 
patients with less diffuse disease but low EF (<35%), who would otherwise be suitable for 
surgery and survive at least a year with good function, may benefit from CABG (Velazques et 
al. 2011). Treating patients without angina is controversial. Few trials addressed to enlighten 
this problem have emerged. Evidence suggests that patients without myocardial viability or 
severely dilated left ventricle show no benefit from revascularization (Authors/Task Force 
Members 2012). 
Some patients amenable to CABG may further benefit from surgical ventricular 
reconstruction (SVR) (Jones et al. 2009). This aims at removing scar tissue from the left 
ventricle to restore the normal morphology. According to guidelines, this procedure should, 
however, be applied only for patients with heart-failure symptoms more predominant than 
their angina, with large LV dimensions, and with transmural scar. In addition, SVR should be 
performed only in centers with long surgical experience (Authors/Task Force Members 2012). 
Regarding secondary valvular problems, effective medical therapy is often the treatment of 
choice, except perhaps for secondary, ischemic mitral regurgitation, which is usually a 
transient dynamic process induced by exercise and might be suitable for repair or 
replacement, for example in combination with revascularization surgery (Authors/Task Force 
Members 2012). 
When heart failure progresses to the end-stage state, surgical options become fewer. Today, 
the gold standard remains heart transplantation (Mehra et al. 2006). To become eligible, 
patients have to meet strict selection criteria, because donor organs are few and the operation 
risky. After transplantation, the patient has to receive life-long immunosuppression with 
consistent risk for severe infections. However, for properly selected patients, it improves 
prognosis, quality of life, and physical capacity (Authors/Task Force Members 2012).  
The number of donor organs cannot meet the increasing number of patients with heart failure. 
Thus, for the treatment of end-stage heart failure, mechanical support devices for the left 
ventricle assist device (LVAD) raise hope (Kirlin et al. 2012). They are now increasingly 
used, instead of as just a bridge therapy to transplantation, rather as a destination therapy for 
patients ineligible for transplantation. When compared to medical therapy, these devices 
improve survival rates (Jokinen et al. 2011, Rose et al. 2001). However, despite some 
potential of LVAD to aid in recovery from heart failure caused by other etiologies (Birks et 
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al. 2011), in patients with ischemic cardiomyopathy and history of myocardial infarction, the 
myocardial destruction is likely to be so extreme that without regeneration of the dead cardiac 
tissue, the heart has no change of true recovery. As foreign material, they also carry risk for 
infections and bleeding, and it is recommended to implant them only after careful 
consideration and in transplantation centers only (Authors/Task Force Members 2012). 
Surgical risks 
Heart failure is a major risk factor affecting survival after all kinds of surgery. It associates 
with both postoperative morbidity and mortality (Rosenberg et al. 2014a and 2014b). Among 
heart-failure patients, even CABG, the most common and least invasive of the 
aforementioned surgical treatments, carries an increased risk of mortality ranging from 3 to 
11% (Vitali et al. 2003). When deciding whether a heart-failure patient should undergo an 
operation, risks must thus be carefully considered.  The risk is especially high for patients 
with EF less than 20 to 30% (Algarni et al. 2011) and with three-vessel disease (Rao et al. 
1996). Their hearts are susceptible to the manipulation encountered during cardiac surgery. 
Heavy blood loss causes hypovolemia and anemia which threaten the failing heart’s capacity 
to keep up with oxygen demand. A cardiopulmonary bypass machine has foreign surfaces that 
can cause coagulopathies and peripheral vasodilation, the etiology of which remains 
unknown. Aortic clamping causes myocardial edema and ischemia, which in combination 
with hypothermia and direct mechanical manipulation of the heart can lead to arrhythmias. 
Possible arrhythmias include atrial fibrillation, affecting 25 to 30% of CABG patients and 
ventricular fibrillation, affecting 1%; mortality to the latter is high, 20-25%. Transient 
atrioventricular block is also common: among CABG patients, it develops in 25% (Rosenberg 
et al. 2014a and 2014b). 
To reduce surgery-related mortality, special attention should focus on patient selection. For 
this purpose, scoring systems are in use to assess the risk to each patient possibly amenable to 
surgery.  In Europe, the European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) and its updated version, EuroSCORE II, have gained popularity. By using 
various patient-related characteristics, for example age, comorbidities, ejection fraction, it can 
well predict individual death risk (Roques et al 2000). 
To prevent adverse events during surgery, hypothermia and chemical protection are useful. 
Hypothermia has a positive effect by reducing cardiac oxygen consumption. Chemical 
cardioplegia solutions boost this decrease. Careful patient monitoring is vital and requires 
invasive techniques. Arterial cannulation and a pulmonary artery catheter (Swan-Ganz 
catheter) are introduced, the former monitoring systemic arterial pressure, and the latter the 
pressures in the right atrium, right ventricle, and pulmonary arteries and the filling pressure of 
the left atrium (pulmonary wedge pressure). Cases of acute exacerbation of heart failure 
require inotropic drugs. To treat postoperative myocardial dysfunction, guidelines (Mebazaa 
et al. 2010) recommend dobutamine and epinephrine, both catecholamines (Fowler et al. 
1984); phosphodiestarase III inhibitors (milrinone) (Wynands et al. 1994); and levosimendan, 
a calcium sensitizer (Raja et al. 2006). Cases of low blood pressure require norepinephrine 
(Mebazaa et al. 2010). 
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Percutaneous interventions 
If an ischemic heart failure patient is not amenable to CABG, proceeding to percutaneous 
coronary intervention (PCI) to relieve angina pectoris symptoms may be one choice for the 
attending physicians. Often, however, coronary artery disease in ischemic heart failure 
patients is diffuse, giving a clear indication for surgery, but if anatomy is suitable, imaging 
indicates viable myocardium, and surgery is not applicable, PCI can be the choice (Windecker 
et al, 2014). 
Because dysfunction of an enlarged ischemic ventricle impairs systolic function, improving 
performance through resynchronization of the ventricular function may be advantageous 
(Nelson et al. 2000). For ischemic heart failure patients, cardiac-resynchronization therapy 
with an implanted pacemaker has proven beneficial (Moss et al. 2009; Tang et al. 2010; 
Cleland et al. 2005; Bristow et al. 2004; Chen et al. 2014). Guidelines recommend this 
therapy for patients expected to survive with good functional status for more than a year, if 
they are in sinus rhythm, their LVEF is ≤30%, they have a prolonged QRS duration (≥150 
ms), and a left bundle branch block seen in electrocardiogram (ECG), irrespective of 
symptom severity. Half of the deaths in heart failure patients occur suddenly and 
unexpectedly, many of which are related to ventricular arrhythmias (McMurray et al. 2012). 
Because antiarrhytmic drugs are not sufficient to reduce risk of death for heart-failure patients 
(Zipes et al. 2006), introducing an implantable cardioverter-defibrillator (ICD) can be 
beneficial, reducing the risk of death as primary prevention (Moss et al. 1996) or secondary 
prevention (The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators 
1997).  
2.1.8 Cardiac imaging of heart failure 
When diagnosing, choosing treatment for, and assessing prognosis of a heart-failure patient, 
imaging techniques play a critical role. These techniques obtain valuable information on heart 
morphology, function, and circulation. 
Important widely used morphological parameters include LV volumetric measurements. 
Luminal volumes of LV in end-diastole (EDV) and in end-systole (ESV) both show 
enlargement especially in systolic dysfunction (McMurray et al. 2012). Use of these two 
volumes yields an estimation of the heart’s EF and stroke volume (SV), that is the volume 
pumped to aorta during one systole. EF is regarded as the best parameter assessing global 
cardiac function and is a major prognostic marker: with lower EF values survival is less 
(Pocock et al. 2006).  
For CAD patients, imaging the obstruction in coronary arteries is important when considering 
the need for revascularization procedures (Task Force Members et al. 2013). Conventionally, 
this can be accomplished by coronary angiography. This technique shows a two-dimensional 
X-ray view of the coronary arteries filled with contrast agent, so that stenotic parts of the 
coronaries are easily detectable. Coronary angiography fails to evaluate the viability of 
myocardium, which is essential when weighing between treatment options. Furthermore, 
hibernating myocardium, the main target of revascularization, cannot remain viable 
indefinitely; delayed revascularization is linked with worse prognosis (Schwarz et al. 1998, 
Shah et al. 2013). 
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2.1.8.1 Echocardiography 
Clinically, a suitable, feasible technique for assessing morphological and functional 
measurements is echocardiography, based on ultra sound. Echocardiography is usually 
performed with a transthoracic approach giving a two- or, less frequently, three-dimensional 
view. A trans-esophageal approach may enable better visualization of the heart but requires 
usually anesthesia. Echocardiography is applicable for diagnosing heart failure and for re-
evaluation of the disease to guide therapy (American College of Cardiology Foundation 
Appropriate Use Criteria Task Force 2011). Although inexpensive and widely available, it has 
limitations, however: its reliability depends quite strongly on the performer’s experience and 
on patient-related factors (subcutaneous fat amount, anatomical variations). Echocardiography 
allows left-ventricular volumes, wall thickness, and ejection fraction to be measured. It also 
gives information about pulmonary arterial pressure, valve function, and the pericardium 
(McMurray et al. 2012). 
2.1.8.2 Nuclear Imaging 
Single-photon emission computer tomography 
 
Single-photon emission computer tomography (SPECT) is in wide clinical use for assessment 
of cardiac perfusion. It takes advantage of three alternative intravenously administered tracers, 
201thallium, 99mtechnetium-sestamibi (99mTc-sestamibi), or 99mtechnetium-tetrofosmin (99mTc-
tetrofosmin), which all give rise to photon emission. The uptake of these tracers by 
myocardial cells depends on myocardial blood flow and active transport. Differences between 
the three tracer alternatives are quite small, but when compared to 201thallium, 99mTc-
sestamibi and 99mTc-tetrofosmin should yield higher energy photons resulting in more 
accurate image quality (Slart et al. 2006). 
 
During the SPECT imaging procedure, a gamma camera records emitted photons at multiple 
projection angles around the patient within a 180- or 360-degree arc. This acquisition process 
continues from one R wave to the next (i.e. one cardiac cycle), and is repeated multiple times 
to generate satisfactory count density and to produce a plot representing cardiac perfusion. 
SPECT imaging can be performed both at rest and after exercise or pharmacological stress. 
Comparing the rest and stress images is common in clinics since it helps in detecting areas 
with inducible coronary blood flow impairment. These areas with low tracer activity in stress 
images but near to normal activity in rest images are suggested as more likely benefiting from 
revascularization procedures (Hachamovitz et al. 2003). 
 
For the detection of CAD, a large trial called the ROBUST study with 2560 patients 
randomized to SPECT with either 201thallium, 99mTc-tetrofosmin, or 99mTc-sestamibi and 
using mainly adenosine stress reported that average sensitivity in the subgroup of patients 
undergoing coronary angiography was 91% and specificity 87% (Kapur et al. 2002). No 
significant difference was detectable between these tracers. In another trial, approximate 
sensitivity of SPECT for predicting global functional cardiac outcome after coronary 
revascularization was 84 and specificity was 68% (Schinkel et al. 2007).  
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Positron emission tomography 
Positron emission tomography (PET) is based on radio nucleotides that give rise to positrons. 
Positron emission results in a positron-electron interaction which leads to their annihilation. 
This produces two 511-kev gamma photons traveling 180 degrees apart. Detection of these 
photons colliding at the same time with a circular detector device leads to acquisition of PET 
images. Even though it was introduced into cardiac applications more than 30 years ago 
(Schelbert et al. 1982; Tillisch et al. 1986), it still has not established a strong position in 
CAD imaging. 
 
PET can serve for both perfusion and viability imaging. Tracers for perfusion studies include 
13N-ammonium and 82rubidium. They have both been extensively described in clinical trials 
showing good sensitivity and specificity for CAD (Machac et al. 2005). Both tracers have a 
short half-life: for 13N-ammonium it is 10 min, and for 82rubidium, only 75 s. Because this 
demands on-site tracer generation, it restricts their clinical use.  
 
PET for viability testing has gained more popularity on a global level since it was introduced 
by Tillisch et al (Tillisch et al. 1986). A traditional metabolic tracer for PET imaging is 18F-
fluorodeoxyglucose (FDG). Its use is based on a shift in metabolism caused by ischemia. In 
ischemic conditions, the heart’s usual preferred energy source, fatty acids, is replaced by 
glucose. FDG behaves similar in heart metabolism to the way glucose does, and is thus a 
convenient tracer to visualize glucose metabolism. Its accumulation in the heart can be 
optimized by simultaneous injection of insulin (also known as the euglycemic 
hyperinsulinemic glucose clamp) and acipimox, a nicotinic-acid derivative, which efficiently 
inhibits the heart’s preferential use of free fatty acids for energy and shifts the cardiac 
metabolism even more towards glucose utilization (Knuuti et al. 1994). 
 
PET is considered an accurate method of assessing myocardial viability (Tillisch et al. 1986; 
Tamaki et al. 1989; DiCarli et al. 1994). In the clinical routine, it is usually evaluated semi-
quantitatively based on the relative regional uptake of FDG scaled to the maximal uptake of 
the heart in question. An experienced physician is required for data analyses (Abraham et al. 
2010). Pooled from various studies, its specificity for predicting global functional cardiac 
outcome after coronary revascularization is calculated to be 83%, with a specificity of 64% 
(Schinkel et al 2007). 
Combining FDG-PET and 99mTc-SPECT 
To increase the accuracy of cardiac viability studies, the latter two study methods have also 
been combined (Zhang et al. 2001; Yamakawa et al. 2004). Normal or elevated FDG tracer 
activity in regions of low perfusion tracer uptake (i.e. perfusion-metabolism mismatch) is 
regarded as presenting areas of hibernating but viable myocardium in potential need of 
revascularization. If both perfusion and FDG accumulation are low (flow-metabolism match) 
the area is interpreted to be scar. In fact, it has been shown that patients with an extensive rest 
perfusion-metabolism mismatch may have an increasing risk of cardiac death when treated 
without revascularization with pharmacotherapy only (Desideri et al. 2005). 
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2.1.8.3 Magnetic Resonance Imaging 
Fundamentals 
Magnetic resonance imaging (MRI) is based on the uneven nuclear numbers of protons and 
neutrons in an atom, particular in hydrogen atoms, which are abundant in the human body. 
They have a magnetic spin, which can be manipulated with a magnetic field aligning them 
parallel and anti-parallel to the direction of the primary field producing a net vector. This 
vector can be modified with a temporary radiofrequency pulse and different pulse sequences 
varying in strength and duration. These pulses are echoed back (i.e. resonated) from the 
patient and the echo data is collected to produce an image. The most common sequences used 
in cardiac MRI are spin and gradient echo (Pettigrew et al. 1999). 
Cardiac volume and function 
The heart is a challenging organ to image because it is constantly moving. Respiratory 
movement affects the heart’s location; thus, most of the MRI study protocols use breath-
holding to avoid artifacts. Heart contractions change cardiac morphology during each cardiac 
cycle. Electrocardiography (ECG) -gating synchronizes imaging with the cardiac cycle. In 
retrospective ECG-gating, ECG and MRI are acquired at the same time but independently. 
Then, a computer calculates retrospectively cardiac phases from the images with the use of 
ECG data. The cardiac cycle can be imaged efficiently (Feinstein 1997). Prospective ECG-
gating, in contrast, binds ECG and MRI tightly throughout the procedure: image acquisition 
starts immediately after one R peak in ECG, which represents the initiation of systole, and 
stops just before the next R peak. 
Left ventricular volume and function are measured from cine images. Common measurements 
are LVEDV and LVESV, LVEF, and myocardial mass. In patients with regional differences 
in heart function caused by, for example, myocardial infarction, local function measurements 
are important. According to American Heart Association (AHA) guidelines (Cerqueira et el. 
2002), LV should be divided into 17 segments (Figure 1). First, three equidistant short-axis 
planes are selected. Then, the ventricular wall in the first two planes is divided into six 
segments and the third one into four segments. The 17th segment is assessed from longitudinal 
images and represents the most apical part of the ventricle. 
Myocardial damage 
When detecting myocardial scar caused by ischemia, late gadolinium enhancement MRI 
(LGE-MRI) has shown major potentiality. It takes advantage of a gadolinium contrast agent 
to distinguish between viable and non-viable tissue. Gadolinium chelate accumulates in areas 
with wide interstitial space. Healthy viable myocardial tissue has minimal interstitial space, 
whereas non-viable tissue containing necrotic and apoptotic cells with ruptured cell 
membranes has substantial amounts of interstitial space. Hence, gadolinium preferentially 
gathers in scar tissue for a longer time (Kim et al. 1996 and 2000). 
For LGE-MRI, gadolinium chelate is administered intravenously. After a delay of 
approximately 5 to 20 minutes, T1-weighed gradient echo-images are acquired. The inversion 
time needs to be correctly adjusted to null the signal intensity of normal myocardium for 
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accurate demarcation of the infarcted area (Edelman 2004). As a result, in the appropriately 
acquired image, viable tissue appears dark, and non-viable bright. 
 
Figure 1. Segmentation model for left ventricle as recommended by American Heart Association. 
Reprinted with Permission, Circulation. 220;105:539-542, ©2002 American Heart Association, Inc. 
http://circ.ahajournals.org/content/105/4/539.full 
 
2.2 Heart regeneration 
The heart has traditionally been regarded as a post-mitotic organ that gains its permanent 
histology and morphology during embryogenesis, when mesoderm contributes to the 
formation of most cardiac cells; a few cells are derived from the cardiac neural crest and 
proepicardium. Early in embryogenesis, mesodermal cells that are destined to become part of 
the heart segregate into two anatomically distinct groups, termed the first and second heart 
fields (Chien et al. 2008). The left ventricular cardiomyocytes are derived from the first heart 
field, for which a unique phenotype marker and pool of specific progenitor cells are as yet 
unestablished (Ptaszek et al. 2012). The second heart field is marked by expression of the 
LIM-homeobox transcription factor Isl1, and its progenitor cells show great multipotency: 
they can give rise to cardiomyocytes in the right and left atria, the right ventricle, the outflow 
tract, the proximal coronary arteries, and most of the conduction system in vivo (Laugwitz et 
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al. 2005). In vitro, human fetal-derived cells expressing ISL1 can be differentiated into the 
three cell lineages present in the heart: cardiomyocyte, smooth muscle and endothelial cell 
lineages (Bu et al. 2009).  
Although already challenged in the 1980’s, only a decade ago, more and more studies 
contradicting the assumption of the adult heart’s inability to regenerate started to emerge and 
gain trust. It soon became evident that also the human heart had mitotic cells that could divide 
(Quaini et al. 1994; Beltrami et al. 2001; Bergman et al. 2009). The regenerative heart cell 
subpopulation is referred to as cardiac progenitor cells (CPC). They have been detected in 
various areas of the heart, including in the atrial appendages and in the outflow tract. 
Although identified by many different laboratories (Beltrami et al. 2003; Messina et al. 2004), 
the exact CPC marker profile is still under debate. Proposed, yet controversial identifying 
markers are c-kit and Sca-1 (both stem cell-related surface antigens) (Garbern and Lee 2013); 
progenitor cells expressing the aforementioned Isl1 seem to be absent from the adult heart 
(Weinberger et al. 2012). Moreover, an epicardial progenitor population expressing an 
embryonic epicardial factor, Wilm’s tumour 1 (Wt1), has been identified in the adult heart. 
These cells reside primarily on the proepicardial surface during embryogenesis, persist in the 
epicardium of the adult mammalian heart, and can proliferate in response to myocardial injury 
and secrete trophic growth factors into the underlying myocardium (Smart et al. 2011; Zhou 
et al. 2011). 
The natural regenerative capacity of CPCs in the adult human heart is, however, quite limited: 
only 1 to 4% of myocardial cells divide after infarction (Beltrami et al. 2001). 
 
2.3 Cell therapy for heart failure  
Despite inert cardiac regenerative capacity the heart cannot repair itself with its progenitor 
cells. Yet, repair of the heart, for example after infarction, is necessary to regain its lost 
function. Thus, in the beginning of the 21st century, finding alternative cell types (Figure 2) to 
establish regenerative cell therapy methods became a popular research area. 
2.3.1 Bone marrow cells 
The bone marrow is a diffuse organ comprising numerous sub-units in the approximately 206 
bones of an adult human. In adults, the bone marrow weighs approximately 2600 g, and 
contains supporting stroma and 1400 g of active blood cell-forming parenchyma (Fliedner et 
al. 2002). The bone marrow contains cells at different stages of regenerative potential, all 
belonging to the mononuclear cell pool. The most potent of them, hematopoietic stem and 
progenitor cells, comprise only 1 to 4% of the bone marrow cells, and are assumed to be 
labeled with the CD34 surface marker, since these cells can restore the whole hematopoietic 
system after myeloablation (Andrews et al. 1992; Berencon et al. 1988). Bone marrow also 
contains non-hematopoietic stem cells, mesenchymal stem cells, capable of differentiating 
into osteoblasts, chondrocytes, adipocytes, and even into cardiomyocytes (Makino et al. 
1999). The number of these cells in the bone marrow is even more limited, ranging from 
0.001 to 0.01% of nucleated cells. 
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Attention has been paid to bone marrow-derived cells and their rather curious wide 
regenerative potential in also other contexts. As noticed in autopsy studies of organ-
transplantation patients, cell chimerism existed in many tissues containing both recipient- and 
donor-derived cells. It soon became evident that bone marrow cells were the origin of this 
chimerism and showed a capability to differentiate into epithelial and neural cells and 
hepatocytes (Mezey et al. 2000; Korbling et al. 2002; Mattsson et al. 2004). Recently, bone 
marrow-derived cells have also been useful in tissue engineering of, for example, trachea 
transplants (Macchiarini et a. 2008; Jungebluth et al. 2011) 
In 2001, a study reporting ground-breaking data suggested, that bone marrow cells (BMCs) 
could serve as a potential cell group also for replacing dead myocardial tissue (Orlic et al. 
2001). According to this article, BMCs could form new cardiomyocytes and vasculature when 
injected intramyocardially into areas next to an infarction. 
Later, these cells were shown to integrate into the myocardial structure, enhance angiogenesis 
and secrete growth factors (Fuchs et al. 2001; Kamihata et al. 2001; Orlic et al. 2001; Mäkelä 
et al. 2007; Burchfield et al. 2008; Korf-Klingebiel et al. 2015), even though effects on true 
myocyte regeneration have been challenged (Balsam et al. 2004; Murry et al. 2004). 
Clinical trials with autologous BMCs were started the same year (Assmus et al. 2002) with 
promising results. Since then, dozens of clinical trials throughout the world have emerged, 
either using unfractionated BMCs or special subgroups, such as mesenchymal stem cells 
(Hare et al. 2012). Results have, however, been mixed (Donndorf et al. 2011; Delewi et al. 
2012).  
2.3.2 Timing 
Since CAD may be diagnosed behind both acute and chronic symptoms, bone marrow cell 
therapy has also been introduced at various phases of the disease. Trials delivering cell 
therapy for patients with acute myocardial infarction aim at preventing myocardial damage 
from occurring. Unfortunately, a large number of patients never visit a hospital in this acute 
phase of disease progression, but visit a hospital after years of dyspnea and chest pain with 
permanently compromised heart function. At this point, the aim of cell therapy is to convert 
the on-going detrimental cardiac remodeling process in order to upgrade cardiac performance. 
It has also been speculated that it could actually be even more beneficial to wait until the 
acute infarction-induced harmful cytokine storm has abated, and the cellular environment in 
the heart has gained integrity in its structure. 
2.3.3 Cell delivery routes 
Several routes for cell therapy administration (Figure 2) have been studied to find the safest, 
most reliable, and efficient means for maximal cell retention. The most popular methods are 
catheter-based intracoronary and transendocardial injections and direct intramyocardial 
epicardial injections. 
The intracoronary technique has been quite popular, especially in clinical trials, due to its 
non-invasive nature. When compared to the other two delivery routes, however, with this 
technique, a more worrisome number of cells are flushed away from the heart to other tissues, 
like the lungs (Hou et al. 2005; Mäkelä et al. 2009). In clinical trials, it is usually applied soon 
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after acute myocardial infarction (AMI) in combination with early revascularization with PCI. 
A recent meta-analysis evaluated 24 randomized clinical trials (RCTs). These trials allocated 
1624 patients to intracoronary cell therapy or standard therapy for AMI. The meta-analysis 
concluded that intracoronary BMC treatment leads to a modest improvement in LVEF: the 
mean difference in improvement in LVEF within 6 months was 2.23% [95% cofidence 
interval (CI), 1.00 to 3.47; P<0.001], favoring patients receiving intracoronary cell therapy. 
At 12 months of follow-up, this difference was sustained, with 3.91% more LVEF 
improvement (95% CI, 2.56 to 5.27; P <0.001). Sustained reduction in LVESV was also 
detectable, but with no significant effect on LVEDV or infarct size (Delewi et al. 2012). 
The intramyocardial transendocardial technique is a more novel catheter-based method used 
also for patients with chronic myocardial ischemia (Beeres et al. 2006 and 2007). Being not 
so invasive, transendocardial cell delivery might also be applicable for severely ill patients 
who could not survive an open-heart surgery. With the aid of evolving imaging techniques, 
this technique will, one hopes, also gain more accuracy and reliability. Thus far, it has shown 
encouraging results. In a trial by van Ramshorst et al (2009), LVEF improvement was 
significantly greater in bone marrow cell–treated patients (change, 3%; 95% CI, 0.5% to 4.7% 
vs −1%; 95% CI, −2.1 to 1.1; P = 0.03). No significant differences were detectable in 
LVEDV and LVESV; scar size was not analyzed. 
In contrast to these two techniques, intramyocardial epicardial injections are applied with the 
aid of direct visualization of the heart and injection sites, and in addition, cell retention is 
apparently most efficient (Hou et al. 2005; Mäkelä et al. 2009), leading to its being regarded 
as the most reliable means of cell delivery (Dib 2010 and 2011). This technique is usually 
applied in combination with cardiac surgery. Clinical trials using this approach have emerged, 
although few have been RCTs, and even fewer have included placebo treatment. A meta-
analysis assessing 6 trials (4 RCTs, 2 cohort studies) showed a 5.40% difference in mean 
LVEF improvement (95% CI, 1.36–9.44; P=0.009) favoring BMC treatment. A trend toward 
a reduction in LVEDV by BMC treatment was apparent. LVESV and scar size were not 
analyzed in the meta-analysis (Donndorf et al. 2011). 
2.3.4 Other cell types 
Another cell type used in the earliest cell therapy clinical trials is skeletal myoblasts. The first 
clinical trial combining injections of these cells during CABG started in 2000 and suggested a 
measurable positive systolic effect. Later, also a multicenter study emerged (Menasché et al. 
2008). One alarming event was a trend towards increased ventricular arrhythmias in the 
myoblast-treated group, although no difference was detectable in comparison with the control 
group that reached the level of significance. Despite promising findings in the early small 
cohort studies, myoblast therapy in this multicenter trial failed to improve regional or global 
LV function beyond that seen in control patients. 
After mixed results with trials with quite well-differentiated cell types (unfractionated BMCs, 
skeletal myobalsts), interest in using more potent, “second generation” cell types (Takashima 
et al. 2013) has been increasing. Fat tissue has recently become one source of cells in cell 
therapy for myocardial infarction, as it also contains a small population of mesenchymal-like 
stem cells, ones possibly capable of producing beneficial regenerative paracrine factors as 
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well as even differentiating into cardiomyocytes (Gimble et al. 2007). In the PRECISE trial 
(Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non 
Revascularizable Ischemic Myocardium), autologous adipose-derived regenerative cells were 
injected transendocardially to treat patients with ischemic cardiomyopathy. The authors 
reported an improvement in global wall-motion score index in the cell treatment group by 
MRI, plus better preservation of maximal oxygen consumption; echocardiography analyses, 
however, revealed no effect on volume or function (Perin et al. 2014). 
From 2011 to 2012, primary reports from two independent clinical trials using CPCs for cell 
therapy appeared, launching the third generation of cell therapy (Takashima et al. 2013). In 
the SCIPIO trial (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy), CPCs were 
isolated from atrial appendages and infused via coronary arteries (Bolli et al. 2011), whereas 
in the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse 
ventricUlar dySfunction), CPCs were isolated from endomyocardial biopsies and also infused 
via coronary arteries (Makkar et al. 2012). Both trials have reported safety data, with no 
special adverse events detected. In the SCIPIO trial, the authors reported an increase in both 
LVEF and regional function, and a decrease in myocardial scar size in 9 of the 20 treated 
patients, who underwent MRI. However, no comparisons were made with the control group 
for these parameters, because no control patients underwent MRI (Chugh et al. 2012). In the 
CADUCEUS trial, comparison of 1-year follow-up data from 17 CPC-treated patients and 8 
controls revealed a reduction in scar size and an improvement in regional function of infarcted 
myocardium in the treatment group (Malliaras et al. 2014).  
Targeting cells with even more regenerative potential, a research group located in France 
recently announced the launch of a phase I clinical trial for treatment of myocardial infarction 
taking advantage of no less than human embryonic stem cells (Menasché et al. 2014). After 
positive results with these cells in preclinical studies in rodents (Tomescot et al. 2007) and 
non-human primates (Blin et al. 2010)—both animal models permanently immunodeprived as 
the allograft requires—the French regulatory agency has approved the group’s project plan for 
a six-patient feasibility and safety trial studying the effect of a stage-specific embryonic 
antigen (SSEA)-1-positive cell population strongly expressing the early cardiac transcription 
factor Isl-1. The trial is currently at its screening phase.   
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Figure 2. Commonly used injection routes for cardiac cell therapy: intramyocardial epicardial 
injection; catheter-based transendocardial injection; and catheter-based intracoronary infusion. 
Different cell types used for cell therapy studies are: A. skeletal myoblasts; B. embryonic stem cells; 
C. adipose-derived stem cells; D. bone marrow cells; E. cardiac progenitor cells. Illustration by 
Vanessa Valero.  
	   29	  
3 Aims of the study 
The main purpose of this study was to assess a cell therapy method combined with coronary 
artery bypass graft surgery (CABG) in the treatment of ischemic heart failure. 
The specific aims were: 
1. Evaluating effects of intramyocardial BMMC injections combined with CABG in the 
treatment of ischemic heart failure with MRI, SPECT, PET, and clinical parameter-scales 
during a 1-year follow-up. (I) 
2. Assessing perioperative patient safety after intramyocardial BMMC injections combined 
with CABG.  (II) 
3. Introducing new standards for clinical testing of novel methods in treatment of ischemic 
heart failure, including state-of-the-art imaging and perioperative safety monitoring. (I-II) 
4. Evaluating effects of the combined BMMC injections and CABG with MRI and clinical 
parameters during extended follow-up. (IV) 
5. Testing whether software-guided analysis of preoperative FDG-PET and 99mTc-SPECT 
can predict CABG outcome. (III) 
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4 Methods 
4.1 Agreements and notifications 
The study protocol was approved by the institutional ethics committee (Dn:o HUS 
456/E6/05). Before its start, the trial was registered at ClinicalTrials.gov (identifier: 
NCT00418418). 
 
4.2 Patient selection 
Patients of either gender were evaluated in our cardiovascular laboratory in Helsinki 
University Central Hospital between the years 2006 and 2010. After evaluation, they were 
scheduled for CABG with moderate heart failure. They were eligible if meeting the following 
inclusion criteria: 1) age between 18 to 75; 2) informed consent available; 3) LVEF between 
≤45% and ≥15%; and 4) NYHA class II to IV heart-failure symptoms. Exclusion criteria 
were: 1) heart failure due to LV outflow-tract obstruction; 2) history of life-threatening 
ventricular arrhythmias or resuscitation, conditions possibly repeating, or an implantable 
cardioverter-defibrillator (ICD); 3) stroke or other disabling condition within 3 months before 
screening; 4) severe valve disease or scheduled valve surgery; 5) other disease limiting life 
expectancy; 6) contraindications for coronary angiogram or MRI; 7) participation in some 
other clinical trial. 
 
Before proceeding to surgery, patients selected for the trial received optimal medication for 
heart failure and coronary disease. At least two heart-failure drugs were included at the 
highest tolerated dose. Alternatives were either an ACE-I or ARB, or a beta-blocker or a 
combination together with diuretics or an aldosterone antagonist (spironolactone). Medication 
for coronary disease was a statin, and anticoagulation by aspirin or clopidogrel. Drug 
optimization continued for 4 to 12 weeks, after which the screening echo was repeated. LVEF 
≤45% meant that the patient could participate in the trial after informed consent. After 
inclusion came CABG scheduling. Baseline studies took place during the waiting period 
before surgery. 
 
4.3 Cell transplantation procedure  
 
4.3.1 BMMC harvesting  
Before starting bone marrow aspiration, anesthesia was induced with etomidate or propofol, 
sufentanil or fentanyl, and rocuronium, and continued with infusions of propofol and 
sufentanil or fentanyl to maintain entropy below 50. 
 
After anesthesia stabilization, the patient was converted from a supine to a prone position, and 
had 100 ml of bone marrow aspirated from each posterior iliac crest and collected in a sterile 
bag containing heparin. The aliquots, once transferred to Helsinki University Meilahti 
Hospital Stem Cell Laboratory, underwent filteration and density-gradient centrifugation 
(Ficoll-Paque Premium, GE Healthcare Bio-Sciences Ab, Uppsala, Sweden) to obtain the 
mononuclear cell fraction, by the standard methods of our laboratory. Finally, the cell 
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suspension was divided into 1-ml syringes, six for each treatment-group patient. Controls 
received the same amount of fluid by syringe but containing only vehicle medium. Treatments 
were masked from the surgeons by a tape covering. 
 
For the BMMC group, cell counts and flow-cytometry for cell-surface markers CD34, 
CD117, CD133, and CD19 of the bone-marrow harvest were performed, by standard methods 
of the laboratory and the FACS Calibur (Beckton-Dickinson, San Jose, CA, USA). 
Monoclonal antibody for CD133 was from Miltenyi Biotech (Auburn, CA, USA), others were 
from Beckton-Dickinson. 
 
4.3.2 Randomization 
Before preoperative examinations, stem-cell laboratory personnel blinded to other participants 
sealed the numbered randomization envelopes. After delivery of the bone marrow harvest to 
the stem cell laboratory, randomization of each patient occurred at the time of the operation. 
 
4.3.3 Operation  
After the harvesting procedure, the patient was converted back to the supine position and 
standard CABG operation began under cardiopulmonary bypass (CPB) and mild 
hypothermia. For starting CPB, intravenous heparin (300 IU/kg) was administered, with an 
additional 5000 IU if needed to achieve the proper activated clotting time of over 480 
seconds.  Dideco Avant or Medtronic provided the membrane oxygenator for CPB. 
Phenylephrine and norepinephrine for hypotension and nitroglycerin for hypertension allowed 
maintenance of the optimal radial artery pressure of 60 to 80 mmHg. To keep blood glucose 
between 4 and 8 mmol/l, insulin was administered. A nonpulsatile oxygen flow of 2.4 
l/min/m², partial pressure of arterial oxygen (PaO2) over 30 kPa, and hematocrit over 22% 
maintained a venous oxygen level (SvO2) over 70%. 
 
After insertion of the aortic cross-clamp, both boluses of cold (12 ᴼC) blood cardioplegia and 
left ventricular venting protected the myocardium. The minimum nasopharyngeal temperature 
during the CPB was 32 to 33 ᴼC. After completion of bypass anastomoses, each patient 
received, under cardiac arrest, 15 to 20 0.2-ml injections containing either BMMCs or placebo 
in the infarction border area; these sites had been decided before surgery by use of imaging 
data. During each surgery, the injection procedure was carefully photographed, and segments 
injected were indicated in patient documents for analysis. 
 
At the end of the operation, rewarming was initiated 20 minutes before removal of the aortic 
cross-clamp to achieve a bladder temperature of over 35 ᴼC while the nasopharyngeal 
temperature remained less than 37 ᴼC. After declamping, the first spontaneous cardiac rhythm 
was recorded and was treated with defibrillation if necessary. Epicardial pacing was also 
administered when necessary. 
   
When the patient was stabilized, weaning from CPB began. Before start of the weaning 
process, patients had to fulfill the following criteria: 1) reperfusion time more than one-third 
of the aortic cross-clamp time; 2) sufficient perfusion pressure; 3) no significant acidosis (pH 
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more than 7.3, BE more than -3); 4) serum potassium 5 to 6 mmol/l; 5) bladder temperature 
more than 35 ᴼC. Pump reduction was 20% at one-minute intervals. Successful weaning 
required an SvO2 over 70%, cardiac index (CI) over 2.2 l/min/m², central venous pressure 
(CVP) under 12 mmHg, and pulmonary capillary wedge pressure (PCWP) under 16 mmHg 
10 min after the termination of pumping in the absence of inotropic agents. If weaning was 
unsuccessful, 10 min of CPB ensued before a reattempt with the aid of epinephrine, 
milrinone, or intra-aortic balloon pump, or a combination, if necessary. To counteract the 
anti-clotting effect of heparin, we administered 1 mg of protamine per 100 IU of the loading 
dose of heparin. 
 
4.3.3 Hemodynamic monitoring during surgery (Study II) 
Throughout anesthesia, the patient’s condition was monitored with hemodynamic 
measurements via a fiberoptic pulmonary artery catheter. We recorded heart rate (HR), mean 
arterial pressure (MAP), CI, mean pulmonary arterial pressure (MPAP), CVP, and PCWP 
with recordings made at the induction, at the opening and widening of the sternum, at the 
beginning of and during CPB, and at the end of the surgery. 
 
4.4 Intensive-care unit stay (Study II) 
After surgery, patients stayed in the intensive care unit (ICU) as long as necessary. To 
optimize recovery, we persued the following aims: 1) CI over 2.2 l/m2; 2) hemoglobin over 
80 g/l; 3) serum potassium over 4.2 mmol/l; 4) blood glucose 4 to 6 mmol/l; 5) SvOₐ over 
70%. The patient was extubated at a bladder temperature of more than 36 ᴼC, when able to 
respond adequately to speech and to maintain adequate spontaneous breathing (10-20 
breaths/min at positive end-expiratory pressure +6 cmH2O, oxygen fraction 40%). 
 
During the first postoperative 24 hours in the ICU, we collected patient data every 4 hours 
including the following: invasive hemodynamics, arterial blood gases, venous oxygen level, 
blood glucose, acid-base balance, lactate, hemoglobin, body temperature, and diuresis. On the 
first postoperative day, we took additional blood tests including pro-B-type amino-terminal 
natriuretic peptide (proBNP), troponin T (TnT), and creatine kinase-myocardial band fraction 
mass (CK-MBm). 
 
4.5 Follow-up 
Patients underwent MRI, PET, and SPECT one week preoperatively and then one year after 
surgery. As a change to our original plan, after encouraging results from that one-year follow-
up, we decided to continue the follow-up and invited the patients for one more follow-up visit 
in spring 2013, when MRI was repeated. Clinical evaluation, and proBNP measurement took 
place preoperatively, one year postoperatively, and at the long-term follow-up in 2013. 
Assessment of current health-related quality of life (HRQoL) took place at the long-term 
follow-up in 2013. 
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4.6 Cardiac MRI (Studies I, III, IV) 
MRI was with a 1.5-T Siemens Sonata scanner and phase array cardiac coil (Siemens AG, 
Erlangen, Germany). Images were gated with ECG and obtained during breath-holding. For 
morphological study and for further orientation data, transaxial haste sequences covered the 
entire heart. Structure and function of the left ventricle we imaged by a standardized MRI 
protocol (Kramer et al. 2008). Truefisp cine series were acquired at the vertical and horizontal 
long axis for a scout to line up short-axis images. From the mitral valve plane through the 
apex, a stack of short-axis images was obtained with slice thickness of 8 mm with a 2-mm gap 
and temporal resolution of 28 to 40 ms. To detect LV scar areas, LGE-MRI imaging was with 
a 2D-segmented inversion recovery gradient echo sequence 12 to 20 minutes after Dotarem® 
(279.3 mg/ml; dose 0.2 mmol/kg) injection. LGE images had identical views and slice/gap 
thickness as cine imaging. Inversion time, determined from a T1-scout sequence, ranged, 
varied between 240 and 300 ms. 
 
For LV volumetry, we analyzed all short-axis cine images with Qmass software (Medis 
Medical Imaging Systems, Leiden, the Netherlands). Endocardial and epicardial contours 
were planimetered at end-diastole and end-systole with papillary muscles included in the 
ventricular blood pool. Planimetry resulted in LVEDV, LVESV, and LVEF. LV was divided 
into 16 segments according to AHA guidelines (Cerqueira et al. 2002), excluding the apical 
segment due to its susceptibility to movement artifacts. For each segment, wall thickening 
(WT) was assessed with Siemens Leonardo workstation and Argus software (Siemens AG), 
and LGE scar volume with Qmass software. For scar tissue, the threshold value was set at 5 
standard deviations (SD) above normal myocardium (Bondarenko et al. 2005); for transmural 
scar the threshold value was set at 50% indicating the percentage of the LGE scar 
encompassing more than 50% of ventricular wall thickness per segment. For each patient, 
pre-and postoperative values for analyses of WT, scar volume, and transmural scar were 
considered as the averages over all injected segments. One investigator analyzed all MRI 
imaging data in random order. 
 
4.7 Nuclear imaging with SPECT and PET (Studies I, III) 
For assessment of viability and hibernating myocardium with PET, FDG served as the tracer. 
After at least 12-hour fasting, patients initially received 250 mg acipimox and acetylsalicylic 
acid 500 mg (to reduce flushing and the vasodilatory effect of acipimox), and one hour later 
again 250 mg acipimox. Another hour later, they received injections of 250 MBq FDG, and 
one hour after the injection the imaging procedure started with the PET computed 
tomography (CT) device (Gemini GXL 16, Philips, Cleveland, OH, USA). First a CT surview 
(30mA, 120 kVp) was obtained, and then, a non-gated FDG-PET scan of the cardiac area (35 
mAs, 140 kVp), 1 hour (16-cm frame, 10 min) and 3 hours (16-cm frame, 15 min) after the 
injection. PET transaxial images were reconstructed by the 3-dimensional Row Action 
Maximum Likelihood (RAMLA) method. The images were converted to short-axis slices, 
each of 4-mm thickness. 
 
Within one week after PET-CT, an ECG-gated rest 99mTc-SPECT at a dose of 250 MBq of 
99mTc-tetrofosmin was performed for assessment of myocardial perfusion. We acquired data 
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at 64 angles using a 64x64 matrix and 30-second frame time with a double-headed ADAC 
Forte SPECT gamma camera (Philips) equipped with low-energy, high-resolution collimators. 
With Cedars AutoSPECT Plus software, 6.6-mm thick gated and summed (non-gated) short-
axis slices were generated. 
4.7.1 Evaluation of nuclear imaging data 
For Study I, FDG polar plot images reconstructed and evaluated in comparison with cardiac 
perfusion SPECT images, allowed assessment of areas of scar (perfusion-metabolism match) 
and ischemic myocardium (perfusion-metabolism mismatch). Analysis was by two blinded, 
experienced nuclear-medicine physicians. By semi-quantitative analysis (semi-quantitative 
polar map displays), FDG uptake was normalized to the zones of maximal perfusion in 
SPECT images. Pre- and postoperative PET studies reporting changes in overall outcome for 
metabolism compared to perfusion changes in SPECT were evaluated and visually scored: 1) 
significant deterioration, 2) mild deterioration, 3) no change, 4) mild improvement, 5) 
significant improvement. 
 
For quantitative analysis of myocardial viability used in Study III, we evaluated FDG-PET 
and summed 99mTc-tetrofosmin-SPECT short-axis images with Emory Cardiac Toolbox 
software (ECT; Syntermed, Inc., Atlanta, GA, USA). We used two quantitative methods 
comparing FDG-PET images to 99mTc-SPECT perfusion images normalized with the program 
supplier’s normal perfusion database. In addition, one method utilized FDG-PET data only. 
 
In the PET-only study, we calculated the size of the nonviable and viable LV tissue in each of 
the three coronary territories and in the total myocardium using thresholds of below 50% for 
nonviable and over 50% for viable tissue. The percentage was calculated from the maximal 
FDG uptake of the LV, and the investigator adjusted the threshold. 
 
For the second and third methods, we applied the normalization protocol provided by the ECT 
program. By comparing them to the normal perfusion database, areas with hypoperfusion 
were identified. These were excluded, and for the remaining normally perfused areas, we 
calculated the average count value. This count then helped to scale the average count value 
for normal areas of FDG study to be equal to that of normal areas of the perfusion study. 
After this, we obtained two overlapping areas representing the normalized perfusion 
distribution and the normalized metabolism distribution.  
 
For the second method (the 10%-threshold method), a threshold of 10% identified an area 
scaled as hypoperfused where FDG uptake value was more than 10 percentage units of the 
perfusion value in the same area. This area was considered as a mismatch, that is, viable but 
hibernating/ischemic myocardium.  
 
For the third method (the 50%-threshold method), a mismatch area was adjusted to be a 
region defined as hypoperfused and had an FDG uptake value of more than 50% of the 
maximal FDG uptake area. In both of these methods, hypoperfused areas with an FDG value 
below the respective threshold were considered as a match, that is, nonviable myocardium. 
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Mismatch and match defect areas we calculated for each of the three coronary territories and 
for the total myocardium. 
4.8 Laboratory parameters, NYHA class, and health-related quality of life 
(Studies I, II, IV) 
Clinical evaluation with NYHA class and proBNP measurement from plasma took place 
preoperatively, one year postoperatively, and for the long-term follow-up in the spring of 
2013. For the long-term follow-up, we measured HRQoL with a questionnaire in spring 2013. 
We chose the SF-36 questionnaire because it has been validated for the Finnish adult 
population (Hagman 1996) and has performed successfully in our institution also previously 
(Jokinen et al. 2010). It is a standardized questionnaire with specified mean and SD values for 
the different dimensions of the instrument per age and gender cohorts. The SF-36 contains 
questions concerning eight dimensions that reflect: 1) physical functioning, measuring 
performance of physical activities (walking shorter or longer distances, lifting heavy objects, 
climbing stairs); 2) role-physical, measuring role limitations (performing work or other daily 
activities) resulting from physical health problems; 3) bodily pain, evaluating limitations in 
performing other daily activities because of pain; 4) subjective general health perceptions and 
future expectations of one's health; 5) vitality, assessing feelings of energy or fatigue; 6) 
social functioning, measuring ability to perform normal social activities; 7) role-emotional, 
assessing role limitations as a result of emotional impairment; and 8) mental health, 
measuring state of mind. The investigator then transformed the scores for each dimension into 
a 0- to 100-point scale for comparisons between groups. A lower score meant greater 
limitations to the person's activity or more distress from social and emotional problems. As a 
reference, we used values for a Finnish cohort with any chronic disease. For comparisons, we 
calculated SF-36 mean scores for our study patients and compared them with means and SD 
of the chosen aggregate of the standardized Finnish population.  
4.9 Statistical analysis 
We concluded from published cell therapy trials involving heart failure that we would achieve 
a power of 80% (with 2-sided alpha of 0.05) with 20 patients per group to detect an up to 8% 
difference in LVEF change. Based on these trials, we estimated a rise in LVEF only in the 
treatment group. Achieving a good marginal would have required enrolling a population of 30 
patients per group. We excluded, however, a large number of patients due to the high efficacy 
of drug therapy optimization that improved their LVEF above our inclusion criteria. We thus 
were able to enroll 20 and 19 patients per group. Variables were tested by Student’s 
independent samples t-test for quantitative normally distributed variables, and by the Mann-
Whitney-U for non-normally distributed variables. For repeated quantitative variables 
measured during the surgery or at the ICU, we used the analysis of variance for repeated 
measures model with Mauchly’s test of sphericity and, if necessary, a Huynh-Feldt correction. 
For correlations of non-normally distributed variables, we calculated Spearman’s coefficient. 
Categorical variables were analyzed with Fisher’s exact test. To test for the impact of the 
differences in length of the extended follow-up periods, we used these lengths as a covariate 
in the ANCOVA model. All P-value testing was two-sided with statistical significance set at 
P<0.05. Computation was achieved with PASW Statistics 18 (IBM Inc., Armonk, NY, USA). 
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5 Results 
 
Figure 3. Study flow diagram of the allocation process. 
5.1 Patient characteristics 
During the selection process, we initially enrolled 104 ischemic heart-failure patients (Figure 
3). They were scheduled for CABG and underwent the preoperative 4- to 12-week (average, 
8-week) pharmacotherapy optimization and standardization period. After this, the screening 
echo was repeated to select patients left with LVEF still remaining ≤45%. The number of 
eligible patients was then 39 (36%). Of these, a randomly selected 18 men and 1 woman 
comprised the controls and 19 men and 1 woman the BMMC group. Patient characteristics 
(Table 2) and drug therapy were similar in both groups preoperatively.  
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 Control  BMMC P 
Number of patients 19  20 1 
Male 18  19 1 
Patient characteristics     
Age (years) 64 
(58-70) 
 65 
(57-73) 
0.74 
Active smoker     8  8 1 
BMI (kg/m²) 28 
(26-31) 
 28 
(25-30) 
0.67 
NYHA class 3 
(2-3) 
 2 
(2-3) 
0.44 
EuroSCORE 4 
(3-5) 
 5 
(3-6) 
0.53 
Logistic EuroSCORE 3.11 
(2.54-4.92) 
 3.80 
(2.32-5.90) 
0.71 
Operative characteristic     
CPB (min) 116 
(102-123) 
 110 
(89-134) 
0.49 
Aortic cross-clamp time 
(min) 
74 
(64-85) 
 73 
(53-89) 
0.73 
Distal anastomoses 4 
(3-4) 
 4 
(3-4) 
0.41 
 
Table 2. Pre- and perioperative patient and surgical characteristics with medians (IQR). 
Since Study III was methodological, we chose to exclude the possible confounding effect of 
BMMC therapy. Thus, we included only the control group in Study III. 
Initially, we had not planned to continue the follow-up after the first postoperative year. 
However, after encouraging results in Study I, we decided to organize one more follow-up 
visit for our patients. In the spring of 2013, we were able to contact 36 of the 39 patients. One 
control patient and 2 BMMC group patients had died after the first postoperative year. Since 
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informed consent from these 3 patients included only participation in the 1-year follow-up, we 
could not include them in Study IV. Six patients refused to participate in the long-term study. 
5.2 Perioperative safety of intramyocardial BMMC therapy (Study II) 
In each group, patients received a median four (IQR 3 to 4) distal anastomoses (P=0.41). 
Measured at four time-points during the operation, all hemodynamic measurements (HR, 
MAP, CI, MPAP, CVP, and PCWP) showed a similar trend between these groups (P>0.05). 
Likewise, throughout their ICU stay, no dissimilarities between the groups were detectable 
either in their hemodynamics (HR, MAP, CI, SI, MPAP, CVP, or PCWP) (P>0.05) or in 
arterial blood gases, acid-base balance, lactate, blood glucose, or hemoglobin levels (P>0.05). 
Between groups, spontaneous rhythm recovery and the need for defibrillation after 
declamping or pacing during surgery were similar between groups. None of the patients 
needed an intra-aortic balloon pump.  
In the morning of the first postoperative day, cumulative diuresis and total fluid balance 
showed no difference between the groups (P>0.05). Moreover, central body temperature 
displayed equivalent trends (P>0.05). Between the groups, the average need for inotropic 
agents (adrenalin, noradrenalin, milrinone) and insulin showed no differences (P>0.05) (Table 
4). To detect perioperative myocardial damage and possible infarction, the level of CK-MBm 
was measured 24 hours after surgery. One patient in the control group had an elevated CK-
MBm up to >100 µg/l; no BMMC-group patient showed any elevation (P=0.47). 
5.3 Predicting myocardial function recovery after revascularization with SPECT 
and PET (Study III) 
Of the 19 control patients, 15 had both MRI and PET-SPECT imaging data that were 
technically satisfactory: one patient refused postoperative studies, one patient received an 
ICD, and two patients’ PET-SPECT image quality was unsatisfactory. One patient showed 
signs of perioperative MI (CK-MBm >100 µg/l during the first postoperative day); for this 
patient, only preoperative imaging data underwent analysis. Thus, pre- and postoperative 
imaging studies of 14 patients were analyzed in Study III.  
 
Of these patients, nine showed clinically significantly improved cardiac function (change in 
LVEF ≥5%). The remaining five showed less marked improvement, no change, or a slight 
deterioration in LVEF; no patients had severe deterioration in LVEF (<-5%). No preoperative 
parameters explained the variation of improvement in LVEF. 
 
With the 10%-threshold method, for each coronary territory, the size of mismatch and match 
areas before surgery correlated significantly with preoperative ventricular wall thickening in 
the respective area, as evaluated with MRI (mismatch: r=-0.33 P=0.03; match: r=-0.40, 
P=0.007).  
 
With the 50%-threshold method, only the preoperative match area showed a significant 
correlation with preoperative wall thickening in the respective coronary territory (mismatch: 
r=-0.21, P=0.16; match: r=-0.45, P=0.002). With the PET-only method, a significant 
correlation also emerged between preoperative defect size and preoperative wall thickening 
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(r=-0.41, P=0.005). No significant correlation was observable for the preoperative total 
myocardial defect size (evaluated by any of the methods) and preoperative LVEF. 
 
For analysis of overall recovery 1 year after CABG, we compared the preoperative mismatch 
and match areas (in 10% or 50% threshold PET-SPECT) and the area with reduced FDG 
(PET-only study) with global functional outcome (change in LVEF) and LV remodeling 
(change in EDV). No correlation appeared with any method. For analysis of local functional 
benefit after CABG, we compared local preoperative defect size evaluated by all three 
methods and local change in WT. Nor on this local level was any correlation observable 
(Table 3). 
 
 
Table 3. Correlation between preoperative FDG-PET/99mTc-SPECT defect area in total myocardium 
and change in LVEF or LVEDV, and between preoperative FDG-PET/99mTc-SPECT defect area and 
change in wall thickening in the respective coronary territory for all patients. 
 
 
We also analyzed PET-SPECT data obtained 1 year postoperatively. According to these 
imaging studies, during follow-up, of the 14, cardiac viability had deteriorated in seven 
patients in three or more of the five defect-size parameters measured. Meanwhile, five of 
these very same patients showed considerably improved LVEF, and all showed reduced 
LVEDV, both evaluated by MRI, and NYHA I-II. When analyzing these five patients in more 
detail, we detected a trend implying that the patients with this discrepancy between 
deteriorated PET-SPECT data but with improved LVEF had preoperatively poorer LVEF and 
a more extensive mismatch area. 
5.4 Effects of intramyocardial BMMC therapy during 1-year follow-up (Study I) 
During the first postoperative year, no mortality occurred. Considering cardiac rhythm 
disturbances, one patient in each group received a permanent PM, and one BMMC-group 
patient an ICD. One BMMC-group patient was diagnosed with a cerebral infarction and 
 LVEDV  LVEF  Wall thickening 
Method Coefficient P  Coefficient P  Coefficient P 
10%-threshold         
Mismatch -0.53 0.05  0.40 0.16  0.04 0.80 
Match 0.16 0.60  -0.46 0.10  0.06 0.73 
50%-threshold         
Mismatch -0.45 0.10  0.30 0.30  0.02 0.89 
Match 0.21 0.48  -0.53 0.05  0.11 0.49 
PET-only 0.14 0.63  -0.50 0.07  0.06 0.72 
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another with a subdural hematoma; one control patient had a cerebral infarction post-
operatively. None of these patients was receiving warfarin. No other hospitalizations caused 
by cardiovascular reasons followed during the 1-year follow-up in either group. 
 
The BMMC patients received injections containing a median 8.4x108 (IQR 5.2x108 
to13.5x108) BMMCs. 
 
Before surgery, the NYHA class median was 3 for controls and 2 for BMMC patients, 
dropping to 1 in each group 1 year postoperatively (P=0.59). Changes in levels of proBNP 
showed no differences between groups (P=0.08).  
 
Because of a PM, an ICD, or of claustrophobia, four patients had contraindications for 
postoperative MRI. Thus, volumetric MRI analyses were successful for 17 patients in the 
control group and 18 in the BMMC group. Analysis of volumetric parameters revealed a 
beneficial change in LVEF (Figure 4) with a median 5.6% among controls (IQR 0.2 to 10.1), 
and 4.8% (IQR -0.5 to 8.2) in the BMMC group (P=0.59). Both groups showed reduced EDV 
and ESV, measured by MRI 1 year postoperatively, with no significant difference between 
groups (Table 4). In injected segments, WT rose by a median 4.5% among controls (IQR -
18.1 to 23.9), and by 5.5% in the BMMC group (IQR -6.6 to 26.5) (P=0.68).  
 
 
 
 
 
Figure 4. Change in LVEF during 1-year follow-up and during extended follow-up, by 2013 with 
individual values (circles, squares), medians (horizontal line), and IQR (whiskers). 
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 Control  BMMC 
 Preop 1-year 2013  Preop 1-year 2013 
EDV 230 175 160  216 195 187 
ml (161-276) (145- 251) (138-195)  (186-323) (165-291) (133-226) 
ESV 127 89 94  121 119 105 
ml (79-200) (63-163) (69-124)  (95-244) (83-186) (73-154) 
EF 36.4 41.5 40.8  37.2 40.4 41.2 
% (27.6-44.0) (36.2-51.9) (34.9-51.1)  (28.9-44.7) (36.1-47.3) (33.4-45.5) 
WT 22 34 44  28 39 39 
% (11-47) (9-49) (25-68)  (8-51) (9-70) (22-59) 
 
Table 4. Left-ventricular volume and function (IQR) measured by MRI at the three timepoints: 
preoperatively, after 1-year follow-up, and at the late follow-up visit in 2013. 
 
LGE-MRI images were technically satisfactory for 31 patients, for 15 controls, and for 16 
BMMC, and were included in scar analyses. Scar volume in injected segments rose by a 
median 5.1% (IQR:-3.3 to 10.8) for controls, but was diminished by 13.1% in the BMMC 
group (IQR -21.4 to -6.5) (P=0.002) (Figures 5,6). For controls, the proportion of transmural 
scar remained unchanged with median change 0% (IQR -2.0 to 13.7) but shrank by a median 
of 16.9% (IQR -29.3 to -5.9) in the BMMC group (P<0.0001). 
 
 
 
Figure 5. Change in scar size after 1-year and extended follow-up with medians and IQR. 
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Figure 6. Individual trends in left-ventricular scar size during the follow-up. 
 
For 33 patients, SPECT-PET imaging follow-up during the first postoperative year was 
successful; 2 controls and 3 in the BMMC group had to be excluded due to insufficient image 
quality, and 1 control patient refused to participate in imaging before CABG. After follow-up, 
changes, as visually assessed by our two experienced nuclear medicine physicians blinded to 
treatments, showed no difference between groups: for controls, the median score for change 
was 4 (IQR 3 to 5) and for the BMMC group, 3 (IQR 3 to 4) (P=0.40).  
 
5.5 Effects of intramyocardial BMMC therapy during long-term follow-up (Study 
IV) 
For the 30 patients willing to participate in the extended follow-up, the median follow-up time 
was eventually 60.7 months (IQR 45.1 to 72.6). 
 
During this period, the difference in median change in plasma levels of proBNP was not 
significant when compared between groups (P=0.36). 
 
For the long-term follow-up, 25 patients (14 controls and 11 BMMC) were analyzed with 
MRI. One control and two BMMC-group patients had contraindications for MRI because of 
ICD or PM. Three control patients and five BMMC patients refused to participate in MRI for 
the long-term follow-up. 
 
After the long-term follow-up, for controls, the median LVEF change was 4.9% (IQR -2.1 to 
12.3) and, for BMMC patients, 3.9% (IQR -5.2 to 10.2) (P=0.65) (Figure 3). LVEDV and 
LVESV showed reductions during follow-up in both groups; no difference in change was 
detectable (P=0.77 and P=0.65, respectively). In injected segments, WT improved by a 
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median 17% (IQR -5 to 30) for controls and 15% (IQR -12 to 19) for BMMC patients 
(P=0.43). Scar size in injected segments increased by a median 2% (IQR -7 to 19) in the 
control group but diminished by a median change of -17% (IQR -30 to -6) in the BMMC 
group (P=0.01) (Figures 4,5). The fraction of transmural scar presented a similar effect from 
BMMC treatment: it remained unchanged (IQR -8 to 25) in placebo-injected segments and 
diminished with a median change of -23% (IQR -36 to -3) in BMMC-injected segments 
(P=0.09). 
We also analyzed changes occurring in the period between the first follow-up visit at one year 
and the late follow-up visit. During this period, WT in the injected segment increased by a 
median of 9% (IQR 2 to 24) for controls and 7% (IQR -16 to 19) for BMMCs (P=0.35). Scar 
size in the injected segments increased by a median of 1% (IQR -14 to 6) in the control group, 
and diminished by a median of 5% (IQR -16 to 8) in the BMMC group (P=0.886) (Figure 5); 
the proportion of transmural scar in the injected segments changed 0% (IQR -25 to 5) and -
1% (IQR -16 to 8), respectively (P=0.931). 
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6 Discussion 
6.1 Selection of patients 
After pooling previous BMMC studies, we had decided to aim at strict inclusion criteria, the 
main limit’s being an LVEF of 15 to 45%. We hypothesized that this more markedly reduced 
LVEF would reveal a clearer benefit from cell therapy, a hypothesis now supported by other 
studies (Yerebakan et al. 2011; Jeevanantham et al. 2012). 
Patients with coronary artery disease and ischemic heart failure are an interesting and also 
important patient group, because the treatment strategy, especially the role of CABG, has yet 
to be clearly established. Hence, studies in search of alternative treatment options are 
warranted. Recently, a randomized trial assessed CAD patients with LVEF <35% assigned to 
groups receiving either medical therapy and CABG or medical therapy alone (Velazques et al. 
2011). They concluded that, between the treatment groups, death from any cause did not 
significantly differ, although patients allocated to CABG, when compared to patients 
receiving medical therapy alone, had lower rates of death from cardiovascular causes and of 
death from any cause or less frequent hospitalization for cardiovascular causes. 
Although CABG seems to be a beneficial choice for treatment of patients with ischemic heart 
failure, we also wanted to treat our patients with optimal pharmacotherapy, which is often 
neglected (Fang et al. 2011). As a consequence, in the screening echo repeated after a period 
of 4 to 12 weeks with optimal, standardized pharmacotherapy, many of our initially selected 
104 patients were no longer eligible because of their improved LVEF. Furthermore, our 
patients presented extensive LV remodeling in terms of LVEDV than did those in similar 
earlier trials (Patel et al. 2005; Hendrix et al. 2006; Mocini et al. 2006; Ahmadi et al. 2007; 
Stamm et al. 2007; Zhao et al. 2008), probably reflecting a more congruent group of patients 
with no further benefit achievable from conservative pharmacotherapy and with less 
endogenous recovery-capacity. 
For the extended follow-up, selected patients became fewer due to unavoidable limiting 
factors. As three patients had died after the one-year follow-up, and six patients refused to 
participate in the extended follow-up for personal reasons, the patient number fell to 30. 
Unfortunately, since three of these patients had also received an ICD or a PM, 
contraindicating MRI, assessing cardiac function and scar changes during the long-term 
follow-up was possible for only 25 patients, making power calculations challenging. This 
patient number is a limitation of our study and demands relative caution when interpreting 
results. 
6.2 Safety 
We wanted also to invest in studying the safety of the cell-injection procedure. Although no 
major concerns had arisen in earlier trials, we had noticed that many trials report safety-
related parameters quite poorly. Safety issues are not of minor importance, since studies have 
demonstrated arrhythmogenic adverse events associated with bone marrow-derived cell 
therapies (Chang et al. 2006; Fukushima et al. 2007). One experimental study also reported 
detecting intramuscular calcification in rats receiving intramyocardial bone marrow cell 
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injections (Yoon et al. 2004). No signs of these kinds of adverse events have appeared in 
clinical trials. 
Currently, cell therapy trials are also aiming at including more severely ill patients, since 
evidence suggests that they may gain more benefits (Yerebakan et al. 2011; Jeevanantham et 
al. 2012). For studies using CABG, this procedure is known to elevate the complication risk: 
low LVEF and triple-vessel disease are linked to more frequent complications during and 
after CABG (Hillis et al. 2011). A few years ago, one clinical trial studying intracoronary 
BMMC injections after PCI to treat patients with a large acute anterior myocardial infarction 
due to occlusion of the proximal left anterior descending artery (LAD) raised concerns of cell 
therapy safety. The reason was that the trial had to be prematurely terminated when 
investigators detected an increase in serious complications in BMMC-treated patients 
(Penicka et al. 2007). Fortunately, none of the complications were related to the injection 
procedure, since most complications occurred before BMMC injections. The study, however, 
underscores the necessity of appropriate patient selection by, for example, excluding patients 
at very high risk for complications from any interventional procedure. 
Concerning peroperative hemodynamics and the need for inotropics, we regarded our study 
procedures as safe. We recorded a vast array of hemodynamic parameters during the surgery 
and in the ICU with no difference between the groups being detectable. Since we included no 
control group treated with CABG only, our results do not elucidate the effects of injection of 
fluid into failing heart muscle but concern only the adverse events of the BMMCs themselves. 
Throughout the follow-up, no tumor formation was observable in any injection area. 
Naturally, to assess longer-term safety of the treatment, Holter recordings for detection of 
arrhythmias would have also been necessary, and this is a limitation of our study. 
6.3 Assessing myocardial function, morphology, and viability with imaging 
methods 
6.3.1 Predicting benefits from revascularization with SPECT and PET 
The main problem with imaging hibernating myocardium, the primary target of 
revascularization, is that none of the available techniques seem to be sufficient alone (DiCarli 
et al. 2002), probably due to their inability to detect different impairments in complex disease. 
Traditional rest SPECT is mainly designed to detect irreversible perfusion defects, further 
refined with stress-SPECT detection of provocation-induced ischemia. FDG-PET identifies 
ischemic shift in metabolism. MRI is the gold standard for function measurement, with 
applicable refinements of LGE-MRI for myocardial scar assessment and low-dose 
dobutamine MRI (LDD-MRI) for assessment of contractile reserve; dobutamine-induced 
stress is also useful for stress echocardiography. Thus, combining different methods to benefit 
from their different advantages and to minimize their disadvantages is a logical approach. 
Some studies have combined SPECT and PET, aiming to obtain even more useful information 
for evaluation of the heart (Zhang et al. 2001; Yamakawa et al. 2004). The purpose of this 
combination is to detect any mismatch in perfusion and metabolism, representing the area of 
viable tissue, tissue presumably benefiting from revascularization. 
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As a sub-study of our cell therapy trial, we also assessed techniques using both SPECT and 
PET imaging for measuring preoperative hibernating but viable tissue and predicting benefit 
from CABG. One technique used PET only, two other techniques combined information from 
both imaging methods with different thresholds. This study included only control patients. To 
gain more feasibility and quantitative accuracy for the traditionally subjective, analyzer-
dependent evaluation method, we used computer software, the Emory Cardiac Toolbox. MRI 
served as the gold standard, measuring change in local and global contractile function during 
the first year after surgery. None of the SPECT-PET methods detecting viable hibernating 
myocardium showed correlations with alteration in functional changes at a global or local 
level. 
Ischemic heart-failure patients are known as a challenge for clinicians trying to choose an 
appropriate treatment (Velazquez et al. 2011). One consensus is that patients with >10% of 
dysfunctional but viable LV myocardium may show more benefit from myocardial 
revascularization, than would patients with ≤10%; this hypothesis, however, remains 
debatable (Desideri et al. 2005; McMurray et al. 2012). Guidelines imply the usefulness of 
several non-invasive imaging techniques in selecting patients for revascularization, although 
without naming any single method as their preference (McMurray et al. 2012). Evidence 
suggests that imaging techniques for detection of viable myocardium that will lead to 
revascularization do improve survival (Bonow et al. 1995; Allman et al. 2002; Bax et al. 
2003). 
Reports of three prospective randomized trials, the Heart Failure Revascularisation (HEART) 
Trial (Cleland et al. 2011), the PET And Recovery following Revascularisation (PARR-2) 
trial (Beanlands et al. 2007), and the Surgical Treatment for Ischaemic Heart Failure (STICH) 
trial (Bonow et al. 2011; Velazquez et al. 2011) have recently appeared addressing the 
question of the need for preoperative imaging. They all challenge the use of non-invasive 
imaging methods, as they failed to find any benefit for guiding patient selection for 
revascularization or any influence on mortality outcome. 
A cautious attitude towards imaging techniques seems justified. We detected a clear 
discrepancy when we compared pre- and postoperative PET- and PET-SPECT-derived data to 
functional changes in MRI: many patients showed an increase in defect size, although their 
LVEF improved significantly, and symptoms were alleviated.  
Many factors account for this heterogeneity between different imaging modalities. All of our 
patients had three-vessel disease, known to complicate analysis of at least perfusion data 
(Aarnoudse et al. 2003; Diamond et al. 2008). A study by Lima et al. (2003) reported that 
SPECT demonstrated neither a significant perfusion defect nor a single-vessel pattern of 
disease in 54% of patients with three-vessel disease as shown by coronary angiography. This 
led to a severe underestimation of the level of compromised perfusion. Another study, by 
Melikian et al. (2010), showed that in patients with multivessel CAD, SPECT tended to 
underestimate or overestimate the significance of coronary stenosis detectable in coronary 
angiography when compared to intracoronary pressure-derived fractional flow reserve (FFR), 
a perfusion gold standard. These discrepancies are likely to be, at least in part, due to 
unreliable distribution of tracers, because of the compromised circulation in three-vessel 
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CAD. In addition, both SPECT and PET show difficulties in detection of subendocardial scar 
(Klein et al. 2002; Wagner et al. 2003). However, as transmural myocardial function depends 
on subendocardial blood flow (Edwards et al. 1992), this may cause confounding effects. 
Considering the different patterns between MRI and nuclear-medicine imaging methods in 
detecting suffering cardiomyocytes, studies have also shown a discrepancy between the 
methods in favor of PET: a higher fraction of cardiomyocytes was reportedly necessary to 
maintain contractile reserve than to achieve radiotracer uptake (Baumgartner et al. 1998; 
Gunning et al. 1998). This implies that the same number of cardiomyocytes fails to show 
viability in function, although showing viability in nuclear imaging studies. Which parameter 
is clinically more relevant is not yet established. 
Today, as recommended by most guidelines, it is mainly patients with three-vessel CAD, 
often accompanied by heart failure, that undergo CABG. Based on our results, it seems clear 
that conventional imaging methods need to evolve as well, since preoperative assessment of 
this patient group is challenging, even with the use of two combined imaging modalities. 
More sophisticated methods are under investigation. One of the potential candidates is PET 
perfusion, at rest and at stress, praised for yielding better image quality (Bateman et al. 2006) 
and identifying more functionally significant stenoses also in three-vessel disease patients 
with balanced ischemia (Beller et al. 2011; Romero et al. 2012). High hopes are also directed 
toward MRI (Hausmann et al. 2004; Gerber et al. 2012; Greenwood et al. 2012). LGE-MRI in 
combination with LDD stimulation is suggested to be the most accurate technique for 
viability detection (Schuster et al. 2012). With their limited availability, for the time being, 
these remain for research purpose only.  
Meanwhile, it is noteworthy that today, despite evolving non-invasive cardiac imaging 
techniques, patients with ischemic heart failure and three-vessel CAD should not be excluded 
from the potential benefits of revascularization solely dependent on imaging-test results 
(Velazquez et al. 2012). 
6.3.2 Evaluating effects of BMMC therapy with MRI 
Our cell therapy study was designed to have as its primary endpoint the change in LVEF after 
one-year follow-up measured by MRI. As secondary endpoints we also had MRI-derived 
parameters: changes in LV volumes, in WT, and in scar size. 
All studies combining intramyocardial BMMC injections with CABG (Patel et al. 2005; 
Mocini et al. 2006; Ahmadi et al. 2007; Stamm et al. 2007; Ang et al. 2008; Zhao et al. 2008; 
Akar et al. 2009), except for two (Hendrikx et al. 2006; Nasseri et al. 2014) used some other 
imaging modality for their primary end-point, most commonly echocardiography. For us, 
however, MRI was an obvious choice because for function and volume analyses it is the gold 
standard. Its high spatial resolution permits localization and later relocalization of the LV 
segments of interest for analyses. MRI should also be superior to PET in resolution capacity, 
especially in assessment of subendocardial scar tissue (Klein et al. 2002); this might also 
explain the failure of PET to identify the fairly small difference in scar change between our 
groups. 
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One critical appraisal pointed out one of the reasons for mixed results in BMMC studies to be 
their heterogeneity in imaging techniques (Wollert et al. 2010). Two independent recent 
publications also suggest that MRI had given more doubtful results (Abbasi et al. 2011; 
Jeevanantham et al. 2012). When using echocardiography or left ventriculography, trials more 
often report significant improvement in LVEF in BMMC-treated patients, and also a trend 
toward improvement when using SPECT. In contrast, the improvement was insignificant with 
MRI. Infarct scar size diminished significantly according to both SPECT and left-
ventriculography, but not MRI  (Jeevanantham et al. 2012). A similar effect emerged in a 
study analyzing trials with a follow-up of more than 2 years: two of the studies there analyzed 
reported a positive BMMC effect on LVEF, neither of which used MRI, whereas three studies 
reporting negative long-term results all had used MRI for assessment of cardiac indexes 
(Abbasi et al. 2011). 
As also noted, attention should be directed at detection also of moderate functional changes 
with state-of-the-art imaging (Wollert et al. 2010), for example, regional WT changes with 
MRI. LVEF may be too rough a variable, especially since its prognostic significance weakens 
with values >45% (Jeevanantham et al 2012). Furthermore, with evolving software, WT 
should be measured truly quantitatively, as in our study, rather than with approximate semi-
quantitative, more subjective scales. Today, insufficiency in technology of automated WT 
tools still requires involvement of an MRI-analysis expert in the data evaluation but software 
under development should provide a solution. 
For future cell therapy studies, another improvement from our study might involve including 
stress-imaging studies. For example, Beller et al. (2011) suggested stress perfusion PET as a 
useful tool for assessing perfusion in new therapies that are supposed to increase myocardial 
blood flow. Moreover, after successful revascularization, viability may improve, although rest 
LVEF remains unchanged; stress LVEF improves similarly between patients with or without 
any positive change in resting LVEF in dobutamine stress echocardiography (Rizzello et al. 
2005). Thus, evaluation of cell therapy effect on viability in future trials might, for example, 
also benefit from even more accurate LDD-MRI. To even further improve evaluation of the 
effects of BMMCs with assessments at a histological level, a tempting option would be 
myocardial biopsies taken after follow-up – an improvement unfortunately not feasible for our 
study. 
6.4 Effects of intramyocardial BMMC injections as an adjunct to CABG 
Our randomized, double-blinded study showed that, as compared to placebo injections, 
BMMC therapy as an adjunct to CABG had no effect either on LVEF - our predefined 
primary endpoint measure – or on local LV wall thickening of the injected segments. Nor was 
any effect on myocardial viability revealed by PET studies. Yet, during the one-year follow-
up, when compared with placebo injections, with BMMC therapy, the amounts of local scar, 
in MRI, diminished statistically significantly. Intriguingly, the difference in change in scar 
size was sustained also in the long-term follow-up. 
Similar studies have suffered from short follow-up times (Donndorf et al. 2011), and even in 
studies using other delivery routes, longer-term follow-ups are few (Beitnes et al. 2009; 
Meyer et al. 2009; Yousef et al. 2009; Leistner et al. 2011; Assmus et al. 2014). This can be 
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disadvantageous, because after revascularization, recovery of hibernating myocardium may 
need several months to evolve; premature assessment may thus rely too much on chance and 
lead to misinterpretation of results of functional recovery. Haas et al. (2001) reported that 
myocardial injury is usually present in various degrees, both stunned and hibernating, in the 
same patient. In their study, after one year, 31% of stunned segments showed total functional 
restoration, whereas only 18% of hibernating segments had similarly recovered. For 
postoperative LGE-MRI analysis, after too short a follow-up, postoperative edema after 
successful revascularization and recovered blood flow could presumably compromise scar 
measurement accuracy and hamper detection of scar reduction. Thus, recovery and outcome 
analysis even after our one-year follow-up, but especially after our extended follow-up, may 
be more optimal and reliable than analysis in previous studies. 
Three major meta-analyses concerning BMMC therapy in CAD have emerged recently 
(Donndorf et al. 2011; Delewi et al. 2012; Jeevanantham et al. 2012). Donndorf et al. 
analyzed data derived from studies similar to ours, combining BMMC injections with CABG. 
They concluded that LVEF improved with a mean difference of 5.4% between BMMC 
patients and control patients in favor of cell therapy. As noted earlier, when comparing our 
study to studies analyzed in the Donndorf meta-analysis, it seems that our patients had more 
extensive cardiac remodeling in terms of LVEDV. Although LVEF did improve in both our 
groups postoperatively, this difference from earlier studies could be relevant in explaining 
why no difference was detectable between the groups. Since extensive LV remodeling can 
prevent improvement in LVEF after revascularization, even despite the presence of viability 
(Bax et al. 2004), the case might be that our patients had a significantly more severe degree of 
heart failure, without an inherent capacity to recover beyond the effects of CABG. 
Our protocol for this cell therapy study was thoroughly considered before the start of the trial. 
To improve objectivity, we used prospective, controlled, randomized, double-blinded 
techniques. We wanted to study intramyocardial injections, as they have been regarded as the 
most efficient method of delivery, enabling direct visualization and offering better 
engraftment (Li et al. 2009, Mäkelä et al. 2009). Combination with CABG was logical 
because of the invasive nature of our intramyocardial injection technique.  
Applying this treatment to patients with chronic ischemic heart disease was also a topic of 
deliberation, since, in a stabilized condition, the heart would probably no longer be influenced 
by the acute inflammatory response prevailing after acute myocardial infarction. It would 
have gained integrity in its structure, thus serving as a reliable platform for cell therapy. In 
addition, the longer the period after AMI, the smaller the likelihood of misinterpreting 
spontaneous functional recovery occurring as part of the natural healing process as being a 
benefit from the cell therapy (Behfar et al. 2014). However, this timing of cell injections may 
also affect the potentiality of the treatment. Because the cells might exert at least some of 
their effects through immunomodulation and paracrine effects (Yeghiazarians et al. 2009), 
administering the cells soon after AMI might cause a more pronounced positive outcome. 
Unfortunately,  as we also noted when reading through our patients’ medical history, many 
patients suffer from asymptomatic MIs that are detected only when the heart is already 
extensively remodeled, sometimes many years after the infarction (Mann 1999). Thus, for 
these patients, acute treatment immediately after MI is impossible. At this chronic stage, the 
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injected cells are more likely to alter the remodeling process through their effects on scar and 
extracellular matrix (Figure 7) (Goumans et al. 2014). 
 
Figure 7. Phases of the healing process after myocardial infarction and potential effects of bone 
marrow cell therapy when applied in different phases (based on data from the review article of 
Goumans et al. 2014). MI, myocardial infarction. 
 
The various policies concerning the procedure of harvesting and processing bone marrow-
derived cells for cell therapy studies have also been under discussion (Wollert and Drexler 
2010). As the bone marrow consists of numerous differing cells, the unfractionated BMMC 
sample to be used in cell therapy may contain variable numbers of hematopoietic progenitor 
cells (CD34+ or CD133+), mesenchymal stem cells, and endothelial progenitor cells, as well 
as more lineage-committed subsets of cells (Young et al. 2014). Thus, the cell therapy product 
may vary enormously between trials using different cell-processing methods. Handling of the 
harvested cells before transplantation is also suggested to affect their characteristics, as 
culture media may differ, and incubations times may range from 4 hours to overnight, no 
recommendations for these are yet clear (Behfar et al. 2014). A study comparing differences 
in cell isolation and storage protocols between two clinical trials, REPAIR-AMI (Schachinger 
et al. 2006) and ASTAMI (Lunde et al. 2006), showed that the protocol applied had a major 
impact on cell functionality, potentially explaining the differences in outcomes (Seeger et al. 
2007). Further analyses by REPAIR-AMI investigators further underline emphasis on the 
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protocol used: they concluded that contamination of the bone marrow-derived cell therapy 
product with red blood cells was associated with poorer bone marrow cell viability and poorer 
recovery of LVEF (Assmus et al 2010). 
We utilized a BMMC isolation protocol that is in widespread, decades-long use in stem-cell 
transplantation in clinical practice. Hence, the protocol was highly reproducible and feasible. 
Processing of BMMC transplants during CABG was efficient and reliable, and patients could 
avoid undergoing two separate procedures. Our cell-processing protocol yielded 
unfractionated BMMCs, which are used also in many other trials. Some trials have preferred 
to use one specific subgroup, for example CD34+ or CD133+. However, little evidence 
implies that in clinical trials single-cell populations would have a greater effect than would a 
mixed cell population (Tendera et al. 2009). On the contrary, an interesting finding in one of 
the subgroup analyses in the meta-analysis by Jeevanantham et al. (2012) was that reduction 
in scar size was significantly greater with BMMC therapy than with CD133+/CD34+ cells. 
That meta-analysis was additionally interesting in its findings. It contained pooled data from 
2625 patients including studies with either intracoronary or intramyocardial injections and 
patients with either AMI or chronic ischemic heart disease with the aim to assess efficacy of 
cell therapy and reasons for the mixed results. In line with earlier hypotheses, BMMC 
injections for patients with more reduced preoperative LVEF were associated with superior 
improvement in LVESV and LVEDV when compared to patients with near normal 
preoperative LVEF. Subgroup analyses also showed that although efficacy showed no clear 
difference in treating patients with either chronic ischemic heart disease or AMI, the LVESV 
(P=0.01) and infarct size (P=0.06) seemed to improve – or remodel – more after chronic 
ischemia. BMMC effects on diastolic or autonomic function, unfortunately neither studied in 
our trial but proposed as elements for BMMC-derived improvement (Yao et al. 2008; Piepoli 
et al. 2010; van Ramshorst et al. 2014), went unanalyzed in the meta-analysis. Eventually, no 
clear explanation for result heterogeneity in BMMC clinical trials emerged. The results, 
however, indicated that, when compared to patients who received traditional therapy, BMMC-
treated patients benefitted from the therapy, with a significant reduction in the number of 
recurrent MI, and stent thrombosis. Importantly, BMMC therapy had a statistically significant 
impact on both all-cause and cardiac mortality, suggesting an overall improvement in 
survival. 
Our primary endpoint, change in LVEF, was negative. The discovery of sustained scar 
diminishment with BMMC injections should, however, not be ignored. Detection of reduced 
scar is in line with many study findings (Jeevanantham et al. 2012). Although we found no 
trend towards a better prognosis for BMMC-treated patients during our long-term follow-up, 
scar size has proven an important prognostic parameter after myocardial infarction (Kwon et 
al. 2009; Boye et al. 2011), one even more essential than LVEF (Roes et al. 2007). Although 
heterogeneity in previous trials limits drawing unambiguous conclusions from our interesting 
findings, BMMC therapy seems promising, it challenges standard therapies, and it proves to 
be a potential future treatment alternative for patients with ischemic heart failure. 
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Summary and conclusions 
This study was a prospective, controlled, double-blinded clinical trial evaluating the safety 
and efficacy of bone-marrow cell injections as an adjunct to CABG in the treatment of 
ischemic heart failure. Our study group received intramyocardial BMMC injections, whereas 
a control group received vehicle medium as placebo injections. Study follow-up was 
originally one year, and continued into an extended follow-up with a median follow-up of 5 
years. Effects were analyzed with state-of-the-art imaging. We also studied the role of 
preoperative nuclear medicine imaging in predicting outcome of revascularization in our 
ischemic heart-failure patients. 
1. The effects of intramyocardial BMMC injections combined with CABG were studied 
in a clinical trial with 1-year follow-up. The effects were measured with MRI, PET, 
SPECT, and clinical parameters. The primary endpoint, change in LVEF measured by 
MRI, was negative but, as compared to placebo injections, BMMC therapy led to a 
reduction in local scar size. 
2. During the cell-therapy surgery and the postoperative stay in the ICU, we recorded a 
wide array of safety-related parameters, including hemodynamics, acid-base balance, 
and fluid balance. No differences were detectable between the two study groups. 
3. Of the 104 patients originally evaluated for the trial, 39 remained eligible after the 
pharmacotherapy-optimization period. Thus, when evaluating new therapies for 
treatment of heart failure in clinical trials, for patient selection to be optimal, 
standardization of pharmacotherapy is essential. 
4. Patients included in the original study were invited to an extended follow-up in 2013. 
After this long-term follow-up, differences between the groups in changes in cardiac 
function measured by MRI remained insignificant. However, in the BMMC-treated 
segments, when compared to controls, the significant reduction in scar size was 
sustained. 
5. We evaluated preoperative FDG-PET and 99mTc-SPECT data by three different 
analysis methods, two of which combined data from both studies, and one used FDG-
PET data only. In ischemic heart-failure patients with three-vessel CAD, we measured 
with each technique the size of viable and of non-viable myocardium, and compared 
each to revascularization-induced change in global and local systolic cardiac function 
measured by MRI. None of the methods seemed to predict the benefit received from 
CABG. 
This study suggests BMMC therapy as an adjunct to CABG as safe but with no detectable 
effect on cardiac function. At the site of BMMC injection, myocardial scar size diminished 
significantly, diminishment evident at both one-year follow-up and at the long-term follow-
up. Thus, for patients with ischemic heart failure, BMMC therapy seems to present an 
intriguing potential future-treatment option  
In this study, preoperative myocardial area identified as viable but hibernating in PET-SPECT 
imaging failed to correlate with the change in global or local cardiac function after 
revascularization. Along with earlier studies, this result further challenges the role of PET 
viability- and SPECT perfusion studies in excluding ischemic heart-failure patients with 
three-vessel disease from the potential benefits of revascularization procedures. 
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